Anna Y. Zolotnitskaya

Submitted by Anonymous (not verified) on
Full Name
Anna Y. Zolotnitskaya
Profile Image URL
https://assets.montefioreeinstein.org/profiles/images/Zolotnitskaya_Anna_MD_2x_0.jpg
Type
Provider
Faculty
First Name
Anna
Last Name
Zolotnitskaya
NPI
1316949100
Faculty ID
1899
CMO Specialties
Clinical Terms
Employment Status
Full Time
Patient Type
Pediatric
Department
einstein-dept-pediatrics
Gender
Female
Email
azolotni@montefiore.org
Phone
718-655-1120
Titles
Type
Academic
Department
Department of Pediatrics
Department Link
Rank
Assistant Professor
Division
Pediatric Nephrology
Type
Clinical
Title
Attending Physician, Division of Pediatric Nephrology, Children?s Hospital at Montefiore
Type
Clinical
Title
Assistant Professor of Pediatrics, Albert Einstein College of Medicine
Type
Administrative
Locations
Is Primary
Off
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.80109 41.01639)
Address Line 1
141 South Central Avenue
City
Hartsdale
State
NY
Zip
10530
Location Title
Montefiore At 141 South Central Avenue
Is Primary
On
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.87885 40.88037)
Address Line 1
3415 Bainbridge Avenue
City
Bronx
State
NY
Zip
10467-2403
Location Title
The Children's Hospital at Montefiore
Is Primary
Off
Type
Academic
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.8791698 40.880273)
Address Line 1
Montefiore Medical Center
Address Line 2
3415 Bainbridge Avenue
City
Bronx
State
NY
Zip
10467
Location Title
Montefiore Medical Center
Education and Trainings
Education Type Label
Medical Education
Education Institution
Leningrad Pediatric Medical Institute
Education Type Label
Fellowship
Education Institution
Montefiore Medical Center
Education Type Label
Residency
Education Institution
St Petersburg Medical University Clinic Hosp
Education Type Label
Residency
Education Institution
St Lukes-Roosevelt Hospital Center - Roosevelt Div
Education Type Label
Residency
Education Institution
Soroka Hospital Medical Center
CHAM Provider
On
Professional Title
M.D.
EMR ID
31006
Biography

<p>Anna Zolotnitskaya, MD, is Medical Director, Pediatric Dialysis at the Children&rsquo;s Hospital at Montefiore Einstein and Assistant Professor, Pediatrics at our Albert Einstein College of Medicine. Dr. Zolotnitskaya&rsquo;s clinical focus is on pediatric dialysis and pediatric renal transplantation. She leads a multidisciplinary dialysis team that provides patient-centered, evidence-based care for children and young adults with end-stage kidney disease. </p><p>After obtaining her Doctor of Medicine at St. Petersburg Pediatric Academy in St. Petersburg, Russia, in 1983, Dr. Zolotnitskaya completed her pediatrics internship at the same institution in 1984. She remained there to complete her pediatrics residency in 1989, before completing an additional pediatrics residency at Soroka Medical Center in Beer-Sheva, Israel, in 1994. Following this, Dr. Zolotnitskaya completed a pediatric nephrology fellowship at Montefiore Einstein in 1998, followed by an additional pediatrics residency at Columbia University College of Physicians and Surgeons, St. Luke&rsquo;s-Roosevelt Hospital in 2001. </p><p>Dr. Zolotnitskaya has been principal investigator and co-investigator in clinical trials that investigate medications employed for the care of children with advanced chronic kidney disease. Her work has been published in numerous peer-reviewed journals and abstracts, and she has given several invited presentations. She is also a reviewer for the <em>Journal of Pediatrics: Clinical Practice</em>. </p><p>Dr. Zolotnitskaya is board certified by the American Board of Pediatric Nephrology, the American Board of Pediatrics and the Israeli Board of Pediatrics. She is a member of the American Academy of Pediatrics, the American Society of Nephrology and the American Society of Pediatric Nephrology.

</p>

Is Open Scheduling
Off

Shiu M. Young

Submitted by Anonymous (not verified) on
Full Name
Shiu M. Young
Profile Image URL
https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg
Type
Provider
Faculty
First Name
Shiu
Last Name
Young
NPI
1467742726
Faculty ID
14110
CMO Specialties
Clinical Terms
Employment Status
Full Time
Patient Type
Adult
Department
einstein-dept-medicine
Gender
Female
Email
shiyoung@montefiore.org
Phone
718-904-2400
Titles
Type
Academic
Department
Department of Medicine
Department Link
Rank
Assistant Professor
Division
Hospital Medicine
Locations
Is Primary
On
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.845 40.85026)
Address Line 1
1825 Eastchester Road
City
Bronx
State
NY
Zip
10467-2404
Location Title
Montefiore Weiler Hospital
Is Primary
Off
Type
Academic
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.8460414 40.8489787)
Room
2-76
Address Line 1
Jack D. Weiler Hospital
Address Line 3
1825 Eastchester Road
City
Bronx
State
NY
Zip
10461
Location Title
Jack D. Weiler Hospital
Education and Trainings
Education Type Label
Medical Education
Education Institution
University of Buffalo
Education Type Label
Residency
Education Institution
University of Virginia Health Sciences Center
CHAM Provider
Off
Professional Title
M.D.
EMR ID
5826
Is Open Scheduling
Off

Danny Woo

Submitted by Anonymous (not verified) on
Full Name
Danny Woo
Profile Image URL
https://assets.montefioreeinstein.org/profiles/images/physphoto/Woo_Danny_MD_420x504.jpg
Type
Provider
Faculty
First Name
Danny
Last Name
Woo
NPI
1639272057
Faculty ID
3618
CMO Specialties
Clinical Terms
Employment Status
Full Time
Patient Type
Adult
Department
einstein-dept-medicine
Languages
Italian
Spanish
German
Gender
Male
Email
dawoo@montefiore.org
Phone
718-892-7817
Titles
Type
Academic
Department
Department of Medicine
Department Link
Rank
Assistant Professor
Division
Cardiology
Locations
Is Primary
On
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.84849 40.84667)
Address Line 1
1578 Williamsbridge Road
City
Bronx
State
NY
Zip
10461-6265
Location Title
Montefiore at 1578 Williamsbridge
Is Primary
Off
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.88584 40.87699)
Address Line 1
3201 Grand Concourse
City
Bronx
State
NY
Zip
10468-1247
Location Title
Montefiore Grand Concourse at 3201
Is Primary
Off
Type
Academic
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.8483118 40.8468944)
Address Line 1
Montefiore Medical Center
Address Line 2
1578 Williamsbridge Road
City
Bronx
State
NY
Zip
10461
Location Title
Montefiore Medical Center
Education and Trainings
Education Type Label
Medical Education
Education Institution
SUNY Health Sciences at Stony Brook
Education Type Label
Fellowship
Education Institution
Jacobi Medical Center
Education Type Label
Residency
Education Institution
Jacobi Medical Center
CHAM Provider
Off
Professional Title
M.D.
EMR ID
3880
Is Open Scheduling
Off

Lucia R. Wolgast

Submitted by Anonymous (not verified) on
Full Name
Lucia R. Wolgast
Profile Image URL
https://assets.montefioreeinstein.org/profiles/images/Wolgast_Lucia_MD_2x.jpg
Type
Provider
Faculty
First Name
Lucia
Last Name
Wolgast
NPI
1770881260
Faculty ID
12874
Clinical Terms
Employment Status
Full Time
Patient Type
Adult
Department
einstein-dept-pathology
Gender
Female
Email
lwolgast@montefiore.org
Phone
718-920-6430
Titles
Type
Academic
Department
Department of Pathology
Department Link
Rank
Associate Professor
Type
Administrative
Locations
Is Primary
On
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.88072 40.88002)
Address Line 1
111 East 210th Street
City
Bronx
State
NY
Zip
10461-2401
Location Title
Montefiore Medical Center
Is Primary
Off
Type
Academic
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.8798833 40.8799447)
Building
Central Building
Room
3-014
Address Line 1
Montefiore Medical Center
Address Line 3
111 East 210th Street
City
Bronx
State
NY
Zip
10467
Location Title
Montefiore Medical Center
Education and Trainings
Education Type Label
Medical Education
Education Institution
Hahnemann University School of Medicine
Education Type Label
Fellowship
Education Institution
Montefiore Medical Center
Education Type Label
Residency
Education Institution
Montefiore Medical Center
CHAM Provider
Off
Professional Title
M.D.
Clinical Focus

Hematology and Coagulation<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Antiphospholipid Syndrome<quillbot-extension-portal></quillbot-extension-portal>

EMR ID
4811
Is Open Scheduling
Off

Samson Wiseman

Submitted by Anonymous (not verified) on
Full Name
Samson Wiseman
Profile Image URL
https://assets.montefioreeinstein.org/profiles/images/physphoto/Wiseman_Samson_MD_420x504.jpg
Type
Provider
Faculty
First Name
Samson
Last Name
Wiseman
NPI
1588761316
Faculty ID
10181
Clinical Terms
Employment Status
Full Time
Patient Type
Adult
Department
einstein-dept-medicine
Languages
Spanish
Persian
Gender
Male
Email
swiseman@montefiore.org
Phone
718-933-2244
Titles
Type
Academic
Department
Department of Medicine
Department Link
Rank
Assistant Professor
Division
Cardiology
Locations
Is Primary
Off
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.91729 40.88171)
Address Line 1
2711 Henry Hudson Parkway
City
Bronx
State
NY
Zip
10463-4713
Location Title
Montefiore Riverdale Practice at 2711
Is Primary
On
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.88584 40.87699)
Address Line 1
3201 Grand Concourse
City
Bronx
State
NY
Zip
10468-1247
Location Title
Montefiore Grand Concourse at 3201
Is Primary
Off
Type
Academic
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.8858822 40.8769029)
Address Line 1
Montefiore Medical Center
Address Line 2
3201 Grand Concourse
City
Bronx
State
NY
Zip
10467
Location Title
Montefiore Medical Center
Education and Trainings
Education Type Label
Medical Education
Education Institution
Albert Einstein College of Medicine
Education Type Label
Fellowship
Education Institution
North Shore University Hospital - Manhasset
Education Type Label
Residency
Education Institution
New York University Medical Center
CHAM Provider
Off
Professional Title
M.D.
EMR ID
4748
Is Open Scheduling
Off

Yanhua Wang

Submitted by Anonymous (not verified) on
Full Name
Yanhua Wang
Profile Image URL
https://assets.montefioreeinstein.org/profiles/images/Wang_Yanhua_MD_2x.jpg
Type
Provider
Faculty
First Name
Yanhua
Last Name
Wang
NPI
1689817397
Faculty ID
3701
Employment Status
Full Time
Patient Type
Adult
Department
einstein-dept-pathology
Languages
Chinese
Gender
Female
Email
ywang@montefiore.org
Phone
718-920-4976
Titles
Type
Academic
Department
Department of Pathology
Department Link
Rank
Professor
Tags
me-patientcare-cancer-about-womens-initiative-network
me-patientcare-cancer-research-stem-cell-cancer-biology
Type
Administrative
Locations
Is Primary
On
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.88072 40.88002)
Address Line 1
111 East 210th Street
City
Bronx
State
NY
Zip
10461-2401
Location Title
Montefiore Medical Center
Is Primary
Off
Type
Academic
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.8798833 40.8799447)
Room
463
Address Line 1
Montefiore Medical Center
Address Line 3
111 East 210th Street
City
Bronx
State
NY
Zip
10467
Location Title
Montefiore Medical Center
Education and Trainings
Education Type Label
Medical Education
Education Institution
Weifang Medical College
Education Type Label
Fellowship
Education Institution
Montefiore Medical Center
Education Type Label
Residency
Education Institution
Weifang Medical College
Education Type Label
Residency
Education Institution
Drexel University
Professional Interests

<p><strong>Areas of Research</strong>: Primary research areas are focused on identifying distinctive immunologic and molecular genetic diagnostic and prognostic markers of hematologic neoplasms.</p>
<p><strong>Professional Interests:</strong> Pathological diagnosis of hematopoietic abnormalities, including mature and immature lymphoma/leukemia; myeloproliferative/dysplastic myeloid neoplasms, plasma cell proliferative disorder and other hematological related abnormalities using flow cytometry, immunohistochemistry, cytogentic/FISH and molecular diagnostic tools.</p>
<p>&nbsp;</p>

CHAM Provider
Off
Professional Title
M.D.
Ph.D.
Selected Publications

<p><strong>Selected Recent Publications:</strong></p>
<p><strong>&nbsp;1.</strong><strong>&nbsp; &nbsp;&nbsp;</strong><strong>Yanghua Wang<sup>1</sup></strong>, Adam Gersten<sup>1</sup>, Susana Moleirinho<sup>2,3</sup>, Frank J. Gunn-Moore<sup>2</sup>, Paul A. Reynolds<sup>3</sup>, Michael B. Prystowsky<sup>1 </sup>&nbsp;Fibroblasts in Head Neck Squamous Cell Carcinoma Associated with Peri-neural Invasion Have High Level Nuclear Yap Expression&nbsp; Academic Pathology, 2015<strong>2.&nbsp;&nbsp;&nbsp;&nbsp; </strong></p>
<p><strong>2.</strong>&nbsp; &nbsp; Jose G.M. Arango, Shlomit Goldberg-Stein, <strong>Yanhua Wang</strong> Extranodal Rosai-Dorfman disease: Clinico-pathologic series of thirteen cases and review of the literature American Journal of Clinical Pathology, 2016; 0:1-11</p>
<p><strong>3.&nbsp;&nbsp;&nbsp;&nbsp; </strong>Monica Zell,*, Amer Assal,*, Olga Derman, Noah Kornblum, Ramakrishna Battini, <strong>Yanhua Wang</strong>, Deepa M. Narasimhulu, Ioannis Mantzaris, Aditi Shastri, Amit Verma, Hilda Ye, IraBraunschweig, Murali Janakiram &nbsp;&nbsp;Adult T-Cell leukemia/lymphoma in the Caribbean cohort is adistinct clinical entity with dismal response to conventional chemotherapy Oncotarget, June 2016<strong> <strong>DOI: 10.18632/oncotarget.10223</strong></strong></p>
<p><strong>4.&nbsp;&nbsp;&nbsp;&nbsp; </strong>Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I, Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J,&nbsp;<strong>Wang Y</strong>, Halmos B, Steidl U, Maciejewski JP, Braunschweig I, Verma A. High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort. Leukemia. 2016 Apr 29. doi: 10.1038/leu.2016.74. [Epub ahead of print]</p>
<p><strong>5.&nbsp;&nbsp;&nbsp;&nbsp; </strong>Monica Zell, Amer Assal, Olga Derman, Noah Kornblum, Ramakrishna Battini,<strong> Yanhua Wang</strong>, Deepa M. Narasimhulu, Ioannis Mantzaris, Aditi Shastri, Amit Verma, Hilda Ye, Ira Braunschweig, Murali Janakiram&nbsp;&nbsp; Adult T-Cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy.&nbsp; Oncotarget, Advance Publications 2016</p>
<p><strong>6.&nbsp;&nbsp;&nbsp;&nbsp; </strong>&nbsp;<strong>Yanhua Wang</strong>, Samer Khader, Yonatan Mehlman, Yungtai Lo, Joseph Albanese, Howard Ratech Loss of &alpha;II and &beta;III Spectrin Isoforms in Body Fluids is Associated with Metastasis. Advances in Cytology &amp; Pathology, Volume 2 Issue 1 &ndash; 2017</p>
<p><strong>7.&nbsp;&nbsp;&nbsp;&nbsp; </strong>Etan Marks, Yang Shi, <strong>Yanhua Wang</strong> CD117 (KIT) Is A Useful Marker in The Diagnosis of Plasmablastic Plasma Cell Myeloma, Histopathology, 2017, <strong>DOI:</strong><strong>&nbsp;</strong>10.1111/his.13196</p>
<p><strong>8.&nbsp;&nbsp;&nbsp;&nbsp; </strong>Murali Janakiram , Amit Verma, <strong>Yanhua Wang</strong>, Anjali Budhathoki, Jaime Suarez Londono, Irina Murakhovskaya, Ira Braunschweig &amp; Caterina P.Minniti&nbsp; Accelerated leukemic transformation after haploidentical transplantation for hydroxyurea-treated sickle cell disease, Leukemia &amp; Lymphoma, DOI: 10.1080/10428194.2017.1324158</p>
<p><strong>9.&nbsp;&nbsp;&nbsp;&nbsp; </strong>Zhonghua Li, M.D., Ph.D., John G. Pizzolo, B.S., <strong>Yanhua Wang</strong>, M.D., Ph.D.Utility of Cytocentrifugation Slides in the Flow Cytometry Laboratory: a Single Institution experience, Clinical Pathology Diangosis,&nbsp; Journal of Hematopathology, online, 2017</p>
<p><strong>10.&nbsp; </strong>Michael J. Licata, MD<sup>1</sup>, Murali Janakiram, MD<sup>2</sup>, Yanan Fang, MD<sup>1</sup>, Urvi A. Shah, MD<sup>2</sup>, Amit Verma, MD<sup>2</sup> and <strong>Yanhua Wang</strong>, MD Diagnostic Challenges of Western Adult T-Cell Leukemia/Lymphoma with Unusual Clinical Presentation - Clinical, Histological and Immunophenotypic Analysis, Leukemia &amp; Lymphoma, 2018 VOL. 59, NO. 5, 1188&ndash;1194 https://doi.org/10.1080/10428194.2017.1365862</p&gt;
<p><strong>11.&nbsp; </strong>Evan Himchak, Etan Marks, Yang Shi, <strong>Yanhua Wang</strong>, Did I miss one? Discovering Hidden Co-existing Hematological with Non-Hematological Malignancies, A Single Institutional Review of 100 Collision Tumors, <a title="International journal of surgical pathology." href="https://www.ncbi.nlm.nih.gov/pubmed/29320898">Int J Surg Pathol.</a>&nbsp;2018 Jan 1:1066896917752862. doi: 10.1177/1066896917752862. [Epub ahead of print]</p>
<p><strong>12.&nbsp; </strong>Jesus Anampa, Tamanna Haque, Irina Murakhovskaya, <strong>Yanhua Wang</strong>, Kimo Bachiashvili, Cristian Papazoglu, Kith Pradhan, Ulrich G. Steidl, Joseph A. Sparano, Amit Verma<sup> &nbsp;&nbsp;&nbsp;</sup>Macrocytosis And Dysplastic Anemia Is Associated With The Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib In Metastatic Breast Cancer, Haematologica , Published Ahead of Print on November 30, 2017, as doi:10.3324/haematol.2017.181941</p>
<p><strong>13.&nbsp; </strong>Shaomin Hu, James Szymanski, Zeina Khairy, Yungtai Lo, <strong>Yanhua Wang</strong> Breast pathology and mammography BI-RADS category correlation study &ndash; A single institute experience Annals of Diagnostic Pathology 35 (2018) 11-15</p>
<p><strong>14.&nbsp; </strong>Shah UA,&nbsp;Chung EY,&nbsp;Giricz O,&nbsp;Pradhan K,&nbsp;Kataoka K,&nbsp;Gordon-Mitchell S,&nbsp;Bhagat TD,&nbsp;Mai Y,&nbsp;Wei Y,&nbsp;Ishida E,&nbsp;Choudhary GS,&nbsp;Joseph A,&nbsp;Rice R,&nbsp;Gitego N,&nbsp;Parrish C,&nbsp;Bartenstein M,&nbsp;Goel S,&nbsp;Mantzaris I,&nbsp;Shastri A,&nbsp;Derman O,&nbsp;Binder A,&nbsp;Gritsman K,&nbsp;Kornblum N,&nbsp;Braunschweig I,&nbsp;Bhagat C,&nbsp;Hall J,&nbsp;Graber A,&nbsp;Ratner L,&nbsp;<strong>Wang Y,&nbsp;</strong>Ogawa S,&nbsp;Verma A,&nbsp;Ye BH,&nbsp;Janakiram M. North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies. Blood.&nbsp;2018 Oct 4;132(14):1507-1518. doi: 10.1182/blood-2018-01-824607. Epub 2018 Aug 13.</p>
<h1>&nbsp;</h1>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>

EMR ID
5085
Is Open Scheduling
Off

Dawn M. Wahezi

Submitted by Anonymous (not verified) on
Full Name
Dawn M. Wahezi
Profile Image URL
https://assets.montefioreeinstein.org/profiles/images/Wahezi_Dawn_MD_MS_2x.jpg
Type
Provider
Faculty
First Name
Dawn
Last Name
Wahezi
NPI
1518290725
Faculty ID
11304
Clinical Terms
Employment Status
part-time
Patient Type
Pediatric
Department
einstein-dept-pediatrics
Gender
Female
Email
dwahezi@montefiore.org
Phone
718-696-2405
Titles
Type
Academic
Department
Department of Pediatrics
Department Link
Rank
Associate Professor
Division
Pediatric Rheumatology
Type
Clinical
Title
Chief, Pediatric Rheumatology
Type
Clinical
Title
Director, Pediatric Rheumatology Fellowship Program
Type
Clinical
Title
Associate Professor, Pediatrics
Type
Clinical
Type
Clinical
Type
Clinical
Type
Administrative
Locations
Is Primary
On
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.87885 40.88037)
Address Line 1
3415 Bainbridge Avenue
City
Bronx
State
NY
Zip
10467-2403
Location Title
The Children's Hospital at Montefiore
Is Primary
Off
Type
Academic
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.8790253 40.8803163)
Address Line 1
Children's Hospital at Montefiore
Address Line 2
3415 Bainbridge Avenue
City
Bronx
State
NY
Zip
10467
Location Title
Children's Hospital at Montefiore
Education and Trainings
Education Type Label
Medical Education
Education Institution
State University of NY at Buffalo School of Medicine
Education Type Label
Fellowship
Education Institution
Children's Hospital at Montefiore
Education Type Label
Residency
Education Institution
Children's Hospital at Montefiore
Professional Interests

<p>Dr. Wahezi attended medical school at the University of Buffalo, School of Medicine and Biomedical Sciences. She completed her residency training in Pediatrics at The Children&rsquo;s Hospital at Montefiore, where she stayed on as the inaugural fellow in Pediatric Rheumatology. She subsequently joined the faculty in the Department of Pediatrics at Montefiore and completed a Master&rsquo;s Degree in clinical research through the Einstein-Montefiore Institute for Clinical and Translational Research Program. Dr. Wahezi is currently an Assistant Professor of Pediatrics at the Albert Einstein College of Medicine and serves as the Program Director of the Pediatric Rheumatology Fellowship Program.&nbsp;</p>
<p>Dr. Wahezi has a special interest in juvenile dermatomyositis (JDM) and was awarded the Cure JM Foundation Early Investigator Award for her research in premature atherosclerosis. She has additionally established a pediatric Systemic Lupus Erythematosus (SLE) Cohort and participates in a dedicated, multi-disciplinary pediatric Lupus Nephritis Clinic. Dr. Wahezi is currently engaged in several research projects within the domains of JDM and SLE, contributing to over 40 peer reviewed manuscripts, reviews and scientific abstracts.</p>
<p>Dr. Wahezi is an active member of both the JDM subcommittee and SLE subcommittee within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) and has participated in numerous observational and comparative&nbsp;effectiveness research protocols through this research consortium. &nbsp;</p>

Research Areas
Pediatric Rheumatology, Juvenile Dermatomyositis, Systemic Lupus Erythematosus
CHAM Provider
Off
Professional Title
M.D.
M.S.
Clinical Focus

<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;">Pediatric Rheumatology</span>

Research Focus

Dr. Wahezi has a particular research interest in juvenile dermatomyositis (JDM) and was awarded the Cure JM Foundation Early Investigator Award for her research in premature atherosclerosis.

EMR ID
4724
Biography

<p></p>Dawn Wahezi, MD, MS, is Chief of the Division of Pediatric Rheumatology and Director of the Pediatric Rheumatology Fellowship Program at the Children&rsquo;s Hospital at Montefiore. She is also Associate Professor of Pediatrics at our Albert Einstein College of Medicine.<br /><br />Dr. Wahezi received her Bachelor of Science from Loyola College and earned her Doctor of Medicine at the State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences. She obtained a Master of Science in Clinical Research at Albert Einstein College of Medicine, and did her residency and fellowship training at CHAM.<br /><br />Dr. Wahezi&rsquo;s clinical and research interests include juvenile dermatomyositis (JDM) and juvenile systemic lupus erythematosus (SLE). At CHAM, she established an interdisciplinary clinic and comprehensive patient registry for children with JDM and SLE.. Dr. Wahezi is an active member of the American Academy of Pediatrics Rheumatology Advisory Board and the Childhood Arthritis and Rheumatology Research Alliance (CARRA).<p></p>

Is Open Scheduling
On

Preeti Viswanathan

Submitted by Anonymous (not verified) on
Full Name
Preeti Viswanathan
Profile Image URL
https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/11c985e0-c3c7-11eb-9ea2-7374238588d1.jpg
Type
Provider
Faculty
First Name
Preeti
Last Name
Viswanathan
NPI
1568721736
Faculty ID
13478
CMO Specialties
Clinical Terms
Employment Status
Full Time
Patient Type
Pediatric
Department
einstein-dept-pediatrics
Languages
Tamil
Hindi
Kannada
Gender
Female
Email
pviswana@montefiore.org
Phone
718-741-2450
Titles
Type
Academic
Department
Department of Pediatrics
Department Link
Rank
Assistant Professor
Division
Pediatric Gastroenterology & Nutrition
Type
Clinical
Title
Attending Physician, Division of Gastroenterology, Hepatology and Nutrition, Children?s Hospital at Montefiore
Type
Clinical
Title
Assistant Professor of Pediatrics, Albert Einstein College of Medicine
Locations
Is Primary
On
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.87885 40.88037)
Address Line 1
3415 Bainbridge Avenue
City
Bronx
State
NY
Zip
10467-2403
Location Title
The Children's Hospital at Montefiore
Is Primary
Off
Type
Academic
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.8790253 40.8803163)
Address Line 1
Children's Hospital at Montefiore
Address Line 2
3415 Bainbridge Avenue
City
Bronx
State
NY
Zip
10467
Location Title
Children's Hospital at Montefiore
Education and Trainings
Education Type Label
Medical Education
Education Institution
Kempegowda Institute of Medical Sciences
Education Type Label
Fellowship
Education Institution
Children's Hospital at Montefiore
Education Type Label
Residency
Education Institution
Miami Childrens Hospital
CHAM Provider
On
Professional Title
M.B.,B.S.
EMR ID
5223
Biography

Dr. Viswanathan received her Medical training at Kempegowda Institute of Medical Sciences in Bangalore, India. She then completed her Pediatric Residency at Miami Children?s Hospital and her fellowship at The Children?s Hospital at Montefiore. She has presented her research at national meetings and has received the Best Research Award at Pediatric Research Day Children?s Hospital at Montefiore 2011.

Is Open Scheduling
Off

Amit K. Verma

Submitted by Anonymous (not verified) on
Full Name
Amit K. Verma
Profile Image URL
https://assets.montefioreeinstein.org/profiles/images/Verma_Amit_MD_2x.jpg
Type
Provider
Faculty
Expert
First Name
Amit
Last Name
Verma
NPI
1033299524
Faculty ID
10065
Clinical Terms
Employment Status
Full Time
Patient Type
Adult
Department
einstein-dept-oncology
einstein-dept-medicine
einstein-dept-developmental-molecular-biology
Languages
Hindi
Punjabi
Gender
Male
Email
amit.verma@einsteinmed.edu
Phone
718-430-8761
Titles
Type
Academic
Department
Department of Oncology
Rank
Professor
Division
Medical Oncology
Type
Academic
Department
Department of Medicine
Department Link
Rank
Professor
Division
Oncology & Hematology
Type
Academic
Department
Department of Developmental & Molecular Biology
Department Link
Rank
Professor
Type
Clinical
Title
Interim Chair, Department of Oncology
Tags
me-patientcare-medicaloncology
Type
Clinical
Title
Associate Director, Translational Science, Montefiore Einstein Comprehensive Cancer Center
Tags
me-patientcare-cancer-research-cdtmi-members
me-patientcare-cancer-clinical-blood-bone-marrow
Type
Clinical
Title
Director, Myelodysplastic Syndromes (MDS) Program
Type
Clinical
Title
Director, Hemato-Oncology
Tags
me-patientcare-cancer-clinical-aids-malignancies
Type
Clinical
Title
Co-Director, Blood Cancer Institute
Tags
bci-leaders
Type
Clinical
Title
Professor, Department of Medicine (Oncology)
Type
Clinical
Title
Professor, Department of Developmental & Molecular Biology
Type
Clinical
Type
Administrative
Title
Director, Division of Hemato-Oncology, Montefiore Department of Oncology
Tags
me-patientcare-cancer-research-stem-cell-cancer-biology
Type
Administrative
Title
Associate Director, Translational Science, Montefiore Einstein Comprehensive Cancer Center
Tags
me-patientcare-cancer-research-cancerdormancy-clinicalresearchco-leaders
me-patientcare-cancer-about-associate-directors
Type
Administrative
Title
Interim Chair, Department of Oncology
Type
Administrative
Title
Susan Resnick Fisher Academic Chair in Brain Cancer Research
Locations
Is Primary
On
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.84475 40.84623)
Address Line 1
1695 Eastchester Road
City
Bronx
State
NY
Zip
10461
Location Title
Montefiore Medical Park at Eastchester
Is Primary
Off
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.84563 40.84596)
Address Line 1
1575 Blondell Avenue
City
Bronx
State
NY
Zip
10461-2601
Location Title
Montefiore Medical Park at 1575 Blondell
Is Primary
Off
Type
Academic
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.8459022 40.8504961)
Building
Chanin Building
Room
302B
Address Line 1
Albert Einstein College of Medicine
Address Line 2
Jack and Pearl Resnick Campus
Address Line 3
1300 Morris Park Avenue
City
Bronx
State
NY
Zip
10461
Location Title
Albert Einstein College of Medicine
Education and Trainings
Education Type Label
Medical Education
Education Institution
All-India Institute of Medical Sciences
Education Type Label
Fellowship
Education Institution
University of Illinois at Chicago
Education Type Label
Fellowship
Education Institution
Northwestern University Medical School
Education Type Label
Residency
Education Institution
University of Illinois at Chicago
Professional Interests

<p>https://einsteinmed.edu/labs/amit-verma/</p&gt;
<p><strong style="text-align: justify;">Targeting signal transduction in hematologic malignancies</strong><span style="text-align: justify;">:&nbsp;<br /></span><span style="text-align: justify;">Cytokines play important roles in the regulation of normal hematopoiesis and a balance between the actions of hematopoietic growth factors and myelosuppressive factors is required for optimal production of different hematopoietic cell lineages. The myelodysplastic syndromes (MDS) are collections of heterogeneous hematologic diseases characterized by refractory cytopenias due to ineffective hematopoiesis. These preleukemic disorders are common causes of anemia in the elderly and are rapidly increasing in incidence. We have also demonstrated that the TGF-beta superfamily/smad, IRAK and MAP kinase pathways is overactivated in MDS. Our work has led to clinical trials with Luspatercept, Galunisertib, CA4948, ARRY-614 and various other promising agents in MDS. We are trying to study the molecular mechanisms that lead to the activation of these pathways in MDS and are using small molecule inhibitors in mouse models to target these pathways.&nbsp;</span></p>
<p style="text-align: justify;"><strong>Targeting aberrant stem and progenitor cells in myelodysplastic neoplasms:&nbsp;<br /></strong>We have demonstrated that aberrant stem cells persist during morphological remissions and are involved in relapse. We have identified novel targets against MDS/AML stem cells that are being tested in various studies. We are also conducting sequencing/epigenetic analysis of highly purified human stem cells and evaluating the role of these alterations in transformation of MDS to AML.&nbsp;</p>
<p style="text-align: justify;"><strong>Epigenomic analysis of tumors</strong>: <br />We are using high throughput assays to analyze DNA methylation across the genome and have optimized these assays to work with low amounts of DNA. We have successfully used these assays in conducting an integrative analysis of epigenetic and genetic alterations in various tumor models, including MDS, esophageal cancer, pancreatic cancer and renal cell cancer.</p>
<p style="text-align: justify;"><strong>Clinical studies in Myelodysplastic syndromes</strong>: <br />We have a &ldquo;center of excellence&rdquo; clinic for patients with Myelodysplatic syndromes. We offer a variety of clinical trials for these patients.</p>

Research Areas
Myelodysplastic syndrome (MDS) are hematologic malignancies characterized by ineffective hematopoiesis. We study the molecular pathogenesis of MDS to identify targetable pathways for treatment of this disease.
Specialties
Expert Tags
Areas of Expertise
Blood cancer detection & treatment
9/11 associated cancers
COVID-19 & cancer
Expert Summary

<p>Dr. Verma is a blood cancer expert, who specializes in the research and treatment of blood cancers.</p>

CHAM Provider
Off
Professional Title
M.B.B.S.
Clinical Focus

Dr. Verma conducts clinical studies for patients with MDS and leukemia and offers a variety of clinical trials for these patients.

Research Focus

Dr. Verma conducts laboratory research aimed at discovering new treatments for myelodysplastic syndromes (MDS) and leukemias, and his research has shown that the TGF-beta superfamily/smad, IRAK and MAP kinase pathways are overactivated in MDS. His work has led to clinical trials with Luspatercept, Galunisertib, CA4948, ARRY-614 and various other promising agents in MDS. DR. Verma’s research has shown that MDS and leukemias are caused by aberrant leukemic stem cells and has identified novel targets against MDS/AML stem cells that are being tested in various studies. 

Selected Publications

<ol>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/40424086/&quot; target="_blank">Splicing of erythroid transcription factor is associated with therapeutic response in myelodysplastic syndromes.</a><br/>Aluri S, Ling T, Fraint E, Chakraborty S, Zhang K, Ahsan A, Kravets L, Poigaialwar G, Zhao R, Pradhan K, Cotton A, Bachiashvili K, Yang JI, Budhathoki A, Agarwal B, Gordon-Mitchell S, Carbajal M, Sahu S, Boultwood J, Pellagatti A, Steidl U, Wickrema A, Nandakumar S, Shastri A, Suragani RN, Bowman TV, Crispino JD, Vodala S, <strong>Verma A. J Clin Invest.</strong> 2025 May 27. PMID: 40424086.</li>

<li><a href="https://pubmed.ncbi.nlm.nih.gov/40333990/&quot; target="_blank">Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias.</a><br/>Venkatasubramanian M, Schwartz L, Ramachandra N, Bennett J, Subramanian KR, Chen X, Gordon-Mitchell S, Fromowitz A, Pradhan K, Shechter D, Sahu S, Heiser D, Scherle P, Chetal K, Kulkarni A, Lee D, Zhou J, Myers KC, Tseng E, Weirauch MT, Grimes HL,* Starczynowski DT,* <strong>Verma A</strong>,* Salomonis N.* <strong>Sci Transl Med</strong>. 2025 May 7. PMID: 40333990. *Co Corresponding</li>

<li> <a href="https://pubmed.ncbi.nlm.nih.gov/39316768/&quot; target="_blank">A Weekly Low-Dose Regimen of Decitabine and Venetoclax is Efficacious and Less Myelotoxic in a Racially Diverse Cohort.</a><br />
Goldfinger M, Mantzaris I, Shastri A, Saunthararajah Y, Gritsman K, Sica A, Kornblum N, Shah N, Levitz D, Rockwell B, Shapiro LC, Gupta R, Pradhan K, Xue X, Munoz A, Dhawan A, Fehn K, Comas M, Verceles JA, Jonas BA, Kambhampati S, Shi Y, Braunschweig I, Cooper DL, Konopleva MY, Feldman EJ, <strong>Verma A. <br />
<em>Blood</em></strong>. 2024 Sep 24.PMID: 39316768 </li>
<li> <a href="https://pubmed.ncbi.nlm.nih.gov/39300320/&quot; target="_blank">Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses.</a><br />
DiNardo CD, Verma D, Baran N, Bhagat TD, Skwarska A, Lodi A, Saxena K, Cai T, Su X, Guerra VA, Poigaialwar G, Kuruvilla VM, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Hackman GL, Chaudhry S, Collins M, Sweeney SR, Busquets J, Rathore AS, Deng Q, Green MR, Grant S, Demo S, Choudhary GS, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett GD, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Kornblau S, Daver NG, Naqvi K, Short NJ, Garcia-Manero G, Tiziani S, <strong>Verma A*</strong>, Konopleva M*.<br />
<strong><em>Nat Cancer</em></strong>. 2024 Sep 19. PMID: 39300320 <br />
*CoCorresponding </li>
<li> <a href="https://pubmed.ncbi.nlm.nih.gov/39294495/&quot; target="_blank">Pharmacological restriction of genomic binding sites redirects PU.1 pioneer transcription factor activity.</a><br />
Taylor SJ, Stauber J, Bohorquez O, Tatsumi G, Kumari R, Chakraborty J, Bartholdy BA, Schwenger E, Sundaravel S, Farahat AA, Wheat JC, Goldfinger M, <strong>Verma A</strong>, Kumar A, Boykin DW, Stengel KR, Poon GMK, Steidl U.<br />
<strong><em>Nat Genet</em></strong>. 2024 Sep 18. PMID: 39294495 </li>
<li> <a href="https://pubmed.ncbi.nlm.nih.gov/38521065/&quot; target="_blank">Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscape.</a><br />
Boddu PC, Gupta AK, Roy R, De La Peña Avalos B, Olazabal-Herrero A, Neuenkirchen N, Zimmer JT, Chandhok NS, King D, Nannya Y, Ogawa S, Lin H, Simon MD, Dray E, Kupfer GM, <strong>Verma A</strong>, Neugebauer KM, Pillai MM. <strong><em>Mol Cell</em></strong>. 2024 Apr 18;84(8):1475-1495.e18.PMID: 38521065 </li>
<li> Aminov S*, Giricz O*, Melnekoff DT*, Sica RA*, Polishchuk V, Papazoglu C, Yates B, Wang HW, Sahu S, Wang Y, Gordon-Mitchell S, Leshchenko VV, Schinke C, Pradhan K, Aluri S, Sohn M, Barta SK, Agarwal B, Goldfinger M, Mantzaris I, Shastri A, Matsui W, Steidl U, Brody JD, Shah NN^, Parekh S^, <strong>Verma A</strong>^ Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency <em><strong>JCI</strong></em>, 2024 Feb 20 PMID: 38376944 </li>
<li> Thakkar A, Pradhan K, Duva B, Carre&ntilde;o JM, Sahu S, Thiruthuvanathan V, Campbel S, Gallego S, Bhagat TD, Rivera J, Choudhary G, Olea R, Sabalza M, Shapiro LC, Lee M, Quinn R, Mantzaris I, Chu E, Will B, Pirofski LA, Krammer F, <strong>Verma A</strong>*, Halmos B*&nbsp; Study of efficacy and longevity of immune response to 3rd and 4th doses of COVID-19 vaccines in patients with cancer: a single arm clinical trial&nbsp; <em><strong>Elife</strong></em> 2023, Mar 28;12:e83694. PMID: 36975207 </li>
<li> Levitz D, Saunthararajah Y, Fedorov K, Shapiro LC, Mantzaris I, Shastri A, Kornblum N, Sica RA, Shah N, Konopleva M, Gritsman K, Braunschweig I, Cooper DL, Pradhan K, <strong>Verma A,</strong> Feldman EJ, Goldfinger M. A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML. <em><strong>Clin Cancer Res.</strong></em> 2023 Aug 1;29(15):2774-2780. PMID: 37341641. </li>
<li> Choudhary GS, Pellagatti A, Agianian B, Smith MA, Bhagat TD, Gordon-Mitchell S, Sahu S, Pandey S, Shah N, Aluri S, Aggarwal R, Aminov S, Schwartz L, Steeples V, Booher RN, Ramachandra M, Samson M, Carbajal M, Pradhan K, Bowman TV, Pillai MM, Will B, Wickrema A, Shastri A, Bradley RK, Martell RE, Steidl UG, Gavathiotis E, Boultwood J, Starczynowski DT*, <strong>Verma A</strong>*. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. <strong>Elife</strong></em>. 2022 Aug 30;11:e78136. PMID: 36040792; PMCID: PMC9427103. </li>
<li>Jasra S, Giricz O, Zeig-Owens R, Pradhan K, Goldfarb DG, Barreto-Galvez A, Silver AJ, Chen J, Sahu S, Gordon-Mitchell S, Choudhary GS, Aluri S, Bhagat TD, Shastri A, Bejan CA, Stockton SS, Spaulding TP, Thiruthuvanathan V, Goto H, Gerhardt J, Haider SH, Veerappan A, Bartenstein M, Nwankwo G, Landgren O, Weiden MD, Lekostaj J, Bender R, Fletcher F, Greenberger L, Ebert BL, Steidl U, Will B, Nolan A, Madireddy A, Savona MR, Prezant DJ, <strong>Verma A</strong>. High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster. <strong><em>Nat Med</em></strong>. 2022 Mar 7. PMID: 35256801.</li>
<li>Lee M, Quinn R, Pradhan K, Fedorov K, Levitz D, Fromowitz A, Thakkar A, Shapiro LC, Kabarriti R, Ruiz RE, Andrews EM, Thota R, Chu E, Kalnicki S, Goldstein Y, Loeb D, Racine A, Halmos B, Mehta V, <strong>Verma A</strong>. Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave. <strong><em>Cancer Cell.</em></strong> 2022 Feb 22: PMID: 35219358; PMCID: PMC8860706</li>
<li>Shapiro LC, Thakkar A, Campbell ST, Forest SK, Pradhan K, Gonzalez-Lugo JD, Quinn R, Bhagat TD, Choudhary GS, McCort M, Sica RA, Goldfinger M, Goel S, Anampa JD, Levitz D, Fromowitz A, Shah AP, Sklow C, Alfieri G, Racine A, Wolgast L, Greenberger L, <strong>Verma A</strong>*, Halmos B*. *Co-Corresponding Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. <strong><em>Cancer Cell</em></strong>. 2022 Jan 10;40(1):3-5. PMID: 34838186; PMCID: PMC8595142.</li>
<li>Komrokji RS, Platzbecker U, Fenaux P, Zeidan AM, Garcia-Manero G, Mufti GJ, Santini V, D&iacute;ez-Campelo M, Finelli C, Jurcic JG, Greenberg PL, Sekeres MA, DeZern AE, Savona MR, Shetty JK, Ito R, Zhang G, Ha X, Backstrom JT, <strong>Verma A</strong>. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. <strong><em>Leukemia.</em></strong> 2022 Feb 26. PMID: 35220402.</li>
<li>Pinho S, Wei Q, Maryanovich M, Zhang D, Balandr&aacute;n JC, Pierce H, Nakahara F, Di Staulo A, Bartholdy BA, Xu J, Borger DK,<strong> Verma A</strong>, Frenette PS. VCAM1 confers innate immune tolerance on haematopoietic and leukaemic stem cells. <strong><em>Nat Cell Biol</em></strong>. 2022 Feb 24. PMID: 35210567.</li>
<li>Myer PA, Lee JK, Madison RW, Pradhan K, Newberg JY, Isasi CR, Klempner SJ, Frampton GM, Ross JS, Venstrom JM, Schrock AB, Das S, Augenlicht L, <strong>Verma A</strong>, Greally JM, Raj SM, Goel S, Ali SM. The Genomics of Colorectal Cancer in Populations with African and European Ancestry. <strong><em>Cancer Discov.</em></strong> 2022 Feb 17: PMID: 35176763.</li>
<li>Su H, Jiang M, Senevirathne C, Aluri S, Zhang T, Guo H, Xavier-Ferrucio J, Jin S, Tran NT, Liu SM, Sun CW, Zhu Y, Zhao Q, Chen Y, Cable L, Shen Y, Liu J, Qu CK, Han X, Klug CA, Bhatia R, Chen Y, Nimer SD, Zheng YG, Iancu-Rubin C, Jin J, Deng H, Krause DS, Xiang J, <strong>Verma A*</strong>, Luo M*, Zhao X*. Methylation of dual-specificity phosphatase 4 controls cell differentiation. <em><strong>Cell Rep.</strong></em> 2021 Jul 27;36(4):109421. PMID: 34320342. *Co-Corresponding.</li>
<li>Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, Rahman S, Kim SY, Ko B, Sica RA, Kornblum N, Bachier-Rodriguez L, McCort M, Goel S, Perez-Soler R, Packer S, Sparano J, Gartrell B, Makower D, Goldstein YD, Wolgast L, <strong>Verma A*</strong>, Halmos B*. Seroconversion rates following COVID-19 vaccination among patients with cancer. <em><strong>Cancer Cell</strong></em>. 2021 Jun 5: PMID: 34133951; PMCID: PMC8179248. *Co-Corresponding</li>
<li>Ueda K, Kumari R, Schwenger E, Wheat JC, Bohorquez O, Narayanagari SR, Taylor SJ, Carvajal LA, Pradhan K, Bartholdy B, Todorova TI, Goto H, Sun D, Chen J, Shan J, Song Y, Montagna C, Pellagatti A, Boultwood J, Xiong S, Lozano G, <strong>Verma A</strong>, Steidl U. MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. <em><strong>Cancer Cell</strong></em>. 2021 Apr 12;39(4):529-547.e7. PMID: 33667384.</li>
<li>Weinreb JT, Ghazale N, Pradhan K, Gupta V, Potts KS, Tricomi B, Daniels NJ, Padgett RA, Oliveira SD, <strong>Verma A</strong>, Bowman TV Excessive R-loops Trigger an Inflammatory Cascade Leading to Increased HSPC Production <em><strong>Dev Cell</strong></em>, 2021, Mar 8;56(5):627-640. PMID: 33651979.</li>
<li>Shapiro LC, Mustafa J, Lombardo A, Khatun F, Joseph F, Gillick K, Naik A, Elkind R, Abreu M, Fehn K, de Castro A, Pradhan K, Binakaj D, Nelson R, Paroder M, Uehlinger J, Gritsman K, Alejandro Sica R, Kornblum N, Shastri A, Mantzaris I, Bachier-Rodriguez L, <strong>Verma A</strong>, Braunschweig I, Goldfinger M. Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population. <em><strong>Bone Marrow Transplant</strong></em>. 2021 Jul;56(7):1761-1763. PMID: 33846558.</li>
<li>Thakkar A, Pradhan K, Jindal S, Cui Z, Rockwell B, Shah AP, Packer S, Sica RA, Sparano J, Goldstein DY, <strong>Verma A</strong>, Goel S, Halmos B Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anti-cancer therapy <em><strong>Nature Cancer</strong></em>, 2021, 2: 392&ndash;399.</li>
<li>Mehta V*, Goel S*, Kabarriti R*, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B*, <strong>Verma A*</strong>. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. <em><strong>Cancer Discov</strong></em>. 2020 Jul;10(7):935-941. PMID: 32357994; PMCID: PMC7334098.</li>
<li>List AF, Sun Z, <strong>Verma A*</strong>, Bennett JM, Komrokji RS, McGraw K, Maciejewski J, Altman J, Cheema PS, Claxton DF, Luger SM, Mattison RJ, Wassenaar T, Artz AA, Schiffer CA, Litzow MR, Tallman MS Lenalidomide-Epoetin Alfa versus Lenalidomide-monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin <em><strong>JCO</strong></em>, 2021, Jan 13: PMID: 33439748 *Corresponding.</li>
<li>COVID-19 and Cancer Consortium. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <em><strong>Cancer Cell</strong></em>. 2020 Dec 14;38(6):761-766. PMID: 33176160; PMCID: PMC7598547.</li>
<li>Kuderer NM, Choueiri TK, et al. Mishra S, Lyman GH, Rini BI, Warner JL; COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <em><strong>Lancet</strong></em>. 2020 Jun 20;395(10241):1907-1918. PMID: 32473681; PMCID: PMC7255743.</li>
<li><strong>Verma A</strong>, Suragani RN, Aluri S, Shah N, Bhagat TD, Alexander MJ, Komrokji R, Kumar R. Biological basis for efficacy of activing receptor ligand traps in myelodysplastic syndromes. <strong>J Clin Invest.</strong> 2020 Feb 3;130(2):582-589. doi: 10.1172/JCI133678. Review. PMID: 31961337</li>
<li>Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, D&iacute;ez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, G&ouml;tze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellstr&ouml;m-Lindberg E, Zeidan AM, Ad&egrave;s L, <strong>Verma A</strong>, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. <strong>N Engl J Med.</strong> 2020 Jan 9;382(2):140-151. PMID: 31914241</li>
<li>Bhagat TD, Ahrens DV, Dawlaty M, Zou Y, Baddour J, Achreja A, Zhao H, Yang L, Patel N, Kwak C,&nbsp; Choudhary G, Gordon-Mitchell S, Alluri S, Bhattacharyya S, Yu Y, Bartenstein M, Giricz O, Suzuki M, Sohal D, Gupta S, Batra S, Goggins M, Steidl U, Greally J, Agarwal B, Pradhan K, Banerjee D, Nagrath D*, Maitra A*,&nbsp;&nbsp;<strong>Verma A*.</strong>&nbsp;Lactate-mediated Epigenetic Reprogramming Regulates Formation of Pancreatic Cancer-associated Fibroblasts&nbsp;<strong>Elife,</strong>&nbsp;Oct 30;8, 2019, (In Press)* Equal Contribution&nbsp;PMID: 31663852</li>
<li>Santini V, Valc&aacute;rcel D, Platzbecker U, Komrokji RS, Cleverly AL, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Gueorguieva I, Girvan AC, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Sridharan A, Will B,&nbsp;<strong>Verma A</strong>.&nbsp;Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.&nbsp;<strong>Clin Cancer Res</strong>. 2019 Sep 3. PMID: 31481511</li>
<li>Smith M*, Choudhary GS*, Pellagatti A, Choi K, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan K, Steeples V , Kim S, Steidl U , Salomonis N , Walter M, Komurov K, Boultwood J*,&nbsp;<strong>Verma A</strong>*, Starczynowski D*<br />
U2AF1 mutations induce oncogenic innate immune pathways by regulating the expression of active IRAK4 isoforms in hematologic malignancies.&nbsp;<strong>Nature Cell Bio</strong>&nbsp;2019&nbsp;May;21(5):640-650&nbsp;* Equal Contribution&nbsp;</li>
<li>Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo W, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw K, Bhattacharyya S, Bishop M, Artz A, Thirman M, Moliterno AR, Ji P, Levine RL, Godley LA, Steidl U, Beiker J, List AF, Saunthararajah Y, He C,&nbsp;<strong>Verma A</strong>,* Wickrema A*<br />
Cytokine regulated phosphorylation and activation of TET2 by JAK2 in hematopoiesis <strong>Cancer Discovery</strong>&nbsp;2019 Jun;9(6):778-795&nbsp;* Equal Contribution</li>
<li>Bhagat TD, Ahrens DV, Dawlaty M, Zou Y, Baddour J, Achreja A, Zhao H, Yang L, Patel N, Kwak C,&nbsp; Choudhary G, Gordon-Mitchell S, Alluri S, Bhattacharyya S, Yu Y, Bartenstein M, Giricz O, Suzuki M, Sohal D, Gupta S, Batra S, Goggins M, Steidl U, Greally J, Agarwal B, Pradhan K, Banerjee D, Nagrath D*, Maitra A*,&nbsp;&nbsp;<strong>Verma A*.</strong>&nbsp;Lactate-mediated Epigenetic Reprogramming Regulates Formation of Pancreatic Cancer-associated Fibroblasts&nbsp;<strong>Elife,</strong>&nbsp;Oct 30;8, 2019, (In Press)* Equal Contribution&nbsp;PMID: 31663852</li>
<li>Santini V, Valc&aacute;rcel D, Platzbecker U, Komrokji RS, Cleverly AL, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Gueorguieva I, Girvan AC, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Sridharan A, Will B,&nbsp;<strong>Verma A</strong>.&nbsp;Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.&nbsp;<strong>Clin Cancer Res</strong>. 2019 Sep 3. PMID: 31481511</li>
<li>Smith M*, Choudhary GS*, Pellagatti A, Choi K, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan K, Steeples V , Kim S, Steidl U , Salomonis N , Walter M, Komurov K, Boultwood J*,&nbsp;<strong>Verma A</strong>*, Starczynowski D*<br />
U2AF1 mutations induce oncogenic innate immune pathways by regulating the expression of active IRAK4 isoforms in hematologic malignancies.&nbsp;<strong>Nature Cell Bio</strong>&nbsp;2019 May;21(5):640-650&nbsp;* Equal Contribution&nbsp;</li>
<li>Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo W, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw K, Bhattacharyya S, Bishop M, Artz A, Thirman M, Moliterno AR, Ji P, Levine RL, Godley LA, Steidl U, Beiker J, List AF, Saunthararajah Y, He C,&nbsp;<strong>Verma A</strong>,* Wickrema A*<br />
Cytokine regulated phosphorylation and activation of TET2 by JAK2 in hematopoiesis<br />
<strong>Cancer Discovery</strong>&nbsp;2019 Jun;9(6):778-795&nbsp;* Equal Contribution</li>
<li>Chen J, Kao Y, Sun D, Todorova T, Reynolds D, Narayanagari SR, Montagna C, Will B,&nbsp;<strong>Verma A</strong>*, Steidl U*Myelodysplastic Syndrome Progression to Acute Myeloid Leukemia at the Stem Cell Level&nbsp;<strong>Nature Medicine</strong>&nbsp;2018,&nbsp;Jan;25(1):103-110&nbsp;* Equal Contribution</li>
<li>Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, Bernard L, Bhattacharyya, S. Lopez, R. Pradhan, K. Giricz, O. Ravipati, G. Wong, L. F. Cole, S. Bhagat, T. D. Feld, J. Dhar, Y. Bartenstein, M. Thiruthuvanathan, V. J.&nbsp; Wickrema, A. Ye, B. H. Frank, D. A. Pellagatti, A. Boultwood, J. Zhou, T. Kim, Y. MacLeod, A. R. Epling-Burnette, P. K. Ye, M. McCoon, P. Woessner, R. Steidl, U. Will, B.&nbsp;<strong>Verma, A.&nbsp;</strong>Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells.&nbsp;<strong>J Clin Invest</strong>. 2018 Sep 25. PMID: 30252677</li>
<li>Shah UA, Chung EY, Giricz O, Pradhan K, Kataoka K, Gordon-Mitchell S, Bhagat TD, Mai Y, Wei Y, Ishida E, Choudhary GS, Joseph A, Rice R, Gitego N, Parrish C, Bartenstein M, Goel S, Mantzaris I, Shastri A, Derman O, Binder A, Gritsman K, Kornblum N, Braunschweig I, Bhagat C, Hall J, Graber A, Ratner L, Wang Y, Ogawa S,&nbsp;<strong>Verma A*</strong>, Ye BH*, Janakiram M.* North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies.&nbsp;<strong>Blood.</strong>&nbsp;2018 Aug 13. PMID: 30104217 * Equal Contribution</li>
<li>Landgren O*, Zeig-Owens R*, Giricz O*, Goldfarb D, Murata K, Thoren K, Ramanathan L, Hultcrantz M, Dogan A, Nwankwo G, Steidl S, Pradhan K, Hall C, Cohen HW, Jaber N, Schwartz T, Crowley L, Crane M, Irby S, Webber MP,&nbsp;<strong>Verma A*</strong>, Prezant DJ* Multiple Myeloma and Its Precursor Disease among Firefighters Exposed to the World Trade Center Disaster&nbsp;<strong>JAMA Onc</strong>, 2018 Jun 1;4(6):821-827. PMID: 29710195 &nbsp;* Equal Contribution</li>
<li>Kao YR, Chen J, Narayanagari SR, Todorova TI, Aivalioti MM, Ferreira M, Ramos PM, Pallaud C, Mantzaris I, Shastri A, Bussel JB,&nbsp;<strong>Verma A</strong>, Steidl U, Will B. Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag.&nbsp;<strong>Sci Transl Med</strong>. 2018 Sep 12;10(458). PMID: 30209246</li>
<li>Giricz O, Mo Y, Dahlman KB, Cotto-Rios XM, Vardabasso C, Nguyen H, Matusow B, Bartenstein M, Polishchuk V, Johnson DB, Bhagat TD, Shellooe R, Burton E, Tsai J, Zhang C, Habets G, Greally JM, Yu Y, Kenny PA, Fields GB, Pradhan K, Stanley ER, Bernstein E, Bollag G, Gavathiotis E, West BL, Sosman JA,&nbsp;<strong>Verma AK&nbsp;</strong>The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma.&nbsp;<strong>JCI Insight</strong>. 2018 Jul 25;3(14). PMID: 30046005</li>
<li>Carvajal LA, Ben-Neriah D, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell KM, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa JD, Mantzaris I, Aivado M, Singer RH, Coleman RA,&nbsp;<strong>Verma A</strong>, Steidl U. Dual inhibition of MDMX and MDM2 as a Therapeutic Strategy in Leukemia.&nbsp;<strong>Sci Transl Med</strong>.&nbsp;2018, Apr 11;10(436). PMID: 29643228</li>
<li>Mitchell K, Barreyro L, Todorova TI, Taylor SJ, Antony-Debr&eacute; I, Narayanagari SR, Carvajal LA, Leite J, Piperdi Z, Pendurti G, Mantzaris I, Paietta E,&nbsp;<strong>Verma A</strong>, Gritsman K, Steidl U.&nbsp; IL1RAP potentiates multiple oncogenic signaling pathways in AML.&nbsp;<strong>J Exp Med.</strong>&nbsp;2018 Jun 4;215(6):1709-1727 PMID: 29773641</li>
<li>Bhattacharyya S, Pradhan K, Campbell N, Mazdo J, Vasantkumar A, Maqbool S, Bhagat TD, Gupta S, Suzuki M, Yu Y, Greally JM, Steidl U, Bradner J, Dawlaty M, Godley L, Maitra A,&nbsp;<strong>Verma A,&nbsp;</strong>&ldquo;Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways,&rdquo; &nbsp;<strong>Genome Res</strong>, 2017, Oct 6. PMID: 28986391</li>
<li>Bhagat TD, Chen S, Bartenstein M, Barlowe AT, Von Ahrens D, Choudhary GS, Tivnan P, Amin E, Marcondes M, Sanders MA, Hoogenboezem RM, Kambhampati S, Ramachandra N, Mantzaris I, Sukrithan V, Laurence R, Lopez R, Bhagat P, Giricz O, Sohal D, Wickrema A, Yeung C, Gritsman K, Aplan P, Hochedlinger K, Yu Y, Pradhan K, Zhang J, Greally JM,&nbsp; Mukherjee SM, Pellagatti A, Boultwood J, Will B, Steidl U, Raaijmakers MHGP, Deeg HJ, Kharas MG,&nbsp;<strong>Verma A,&nbsp;</strong>&ldquo;Wnt/&szlig;-catenin activation by epigenetically aberrant stroma drives myelodysplastic syndrome,&rdquo;&nbsp;<strong>Cancer Research</strong>&nbsp;Jul, 2017, PMID: 28684528</li>
<li>Reyna DE, Garner TP, Lopez A, Kopp F, Choudhary GS, Sridharan A, Narayanagari SR, Mitchell K, Dong B, Bartholdy BA, Walensky LD,&nbsp;<strong>Verma A</strong>, Steidl U, Gavathiotis E. Direct &ldquo;Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia,&rdquo;&nbsp;&nbsp;<strong>Cancer Cell</strong>&nbsp;2017 Oct 9.PMID: 29017059&nbsp;</li>
<li>Antony-Debr&eacute; I, Paul A, Leite J, Mitchell K, Kim HM, Carvajal LA, Todorova TI, Huang K, Kumar A, Farahat AA, Bartholdy B, Narayanagari SR, Chen J, Ambesi-Impiombato A, Ferrando AA, Mantzaris I, Gavathiotis E,&nbsp;<strong>Verma A</strong>, Will B, Boykin DW, Wilson WD, Poon GM, Steidl U., &ldquo;Pharmacological inhibition of the transcription factor PU.1 in leukemia,&rdquo; &nbsp;<strong>J Clin Invest</strong>&nbsp;2017 Oct 30, PMID: 29083320</li>
<li>Yue L, Bartenstein M, Zhao W, Ho W, Murdun C, Mailloux AW, Zhang L, Budhakoti A, Pradhan K, Rapaport F, Wang H, Shao Z, Steidl U, Levine RL, Zhao ZJ,&nbsp;<strong>Verma A*,</strong>&nbsp;Epling-Burnette PK* (*Co-Corresponding), &ldquo;Efficacy of ALK5 Inhibition in Myelofibrosis.&rdquo;&nbsp;&nbsp;&nbsp;<strong>JCI Insight&nbsp;</strong>(In Press)</li>
<li>Bhagat TD, Zou Y, Huang S, Park J, Palmer MB, Hu C, Li W, Shenoy N, Giricz O, Choudhary G, Yu Y, Ko YA, Izquierdo MC, Park ASD, Vallumsetla N, Laurence R, Lopez R, Suzuki M, Pullman J, Kaner J, Gartrell B, Hakimi AA, Greally JM, Patel B, Benhadji K, Pradhan K,&nbsp;<strong>Verma A*,</strong>&nbsp;Susztak K* (*Co-Corresponding), &ldquo;Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer .&rdquo; &nbsp;<strong>JBC&nbsp;</strong>2016, Dec 1. PMID: 2790905</li>
<li>Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S , Bhagat T, Bhattacharyya S, Assal A, Shastri A,&nbsp; Gordon-Mitchell S, Pellagatti A, Boultwood J, Schinke C, Yu Y, Guha C, Rizzi J, Garrus J, Brown S, Wollenberg L, Hogeland G, Wright D, Munson M`, Rodriguez M, Gross S, Chantry D, Zou Y, Platanias L, Burgess LE, Pradhan K, Steidl U,&nbsp;<strong>Verma A,</strong>&nbsp; &ldquo;Pexmetinib: a novel dual inhibitor of Tie-2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia.&rdquo;&nbsp;&nbsp;<strong>Cancer Res&nbsp;</strong>2016 Jun 10. PMID: 27287719</li>
<li>Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I,&nbsp; Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J, Wang Y, Halmos B, Steidl U, Maciejewski J, Braunschweig I,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;High Prevalence and Allele Burden Independent Prognostic Importance of p53 Mutations in an Inner-City MDS/AML Cohort,&rdquo; &nbsp;<strong>Leukemia&nbsp;</strong>2016 Apr 29. PMID: 27125205</li>
<li>Taggart J, Ho TC, Amin E, Xu H, Barlowe TS, Perez AR, Durham BH, Tivnan P, Okabe R, Chow A, Vu L, Park SM, Prieto C, Famulare C, Patel M, Lengner CJ,&nbsp;<strong>Verma A,</strong>&nbsp;Roboz G, Guzman M, Klimek VM, Abdel-Wahab O, Leslie C, Nimer SD, Kharas MG. &ldquo;MSI2 is required for maintaining activated myelodysplastic syndrome stem cells.&rdquo;&nbsp;&nbsp;<strong>Nat Commun.</strong>&nbsp;2016 Feb 22;7:10739. PMID: 26898884</li>
<li>Platzbecker U, Wong RS,&nbsp;<strong>Verma A,</strong>&nbsp;Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, G&ouml;tze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A., &ldquo;Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.&rdquo;&nbsp;&nbsp;<strong>Lancet Haematol.</strong>&nbsp;2015 Oct;2(10):e417-26. PMID: 26686043</li>
<li>Sundaravel S, Duggan R, Bhagat TD, Ebenezer D, Liu H, Yu Y, Bartenstein M, Unnikrishnan M, Karmakar S, Liu TC, Anastasi J, McGraw K, Pellagatti A, Boultwood J, Yajnik V, Artz A, Le Beau M, Steidl U, List A, Evans T*,&nbsp;<strong>Verma A</strong>*, Wickrema A*. (*Co-Corresponding),&nbsp; &ldquo;Reduced DOCK4 Expression Leads to Erythroid Dysplasia in Myelodysplastic Syndromes.&rdquo;&nbsp;&nbsp;<strong>PNAS</strong>&nbsp;2015; Nov 17;112(46): PMID: 26578796</li>
<li>Okoye-Okafor UC, Bartholdy B, Cartier J, Gao EN, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A, Wiggall KJ, Reif AJ, Schmidt SJ, Qi H, Zhao H, Joberty G, Faelth-Savitski M, Bantscheff M, Drewes G, Duraiswami C, Brady P, Groy A, Narayanagari SR, Antony-Debre I, Mitchell K, Wang HR, Kao YR, Christopeit M, Carvajal L, Barreyro L, Paietta E, Makishima H, Will B, Concha N, Adams ND, Schwartz B, McCabe MT, Maciejewski J,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U., &ldquo;New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.&rsquo;&nbsp;<strong>Nature Chem Biol</strong>. 2015 Oct 5. PMID: 26436839</li>
<li>PAK1 Pandolfi A, Stanley RF, Yu Y, Bartholdy B, Pendurti G, Gritsman K, Boultwood J, Chernoff J,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U, &ldquo;PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2015 Jul 13. PMID: 26170031</li>
<li>Cabrero M, Yu Y,&nbsp;<strong>Verma A,</strong>&nbsp;Yang H, Colla S, Jia Y, Zheng H, Bohannan Z, Ganan-Gomez I, Futreal A, Takahashi K, Chin L, Kantarjian H, Pellagatti A, Bowman T, Boultwood J, Garcia-Manero G, Wei Y, &ldquo;Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion.&rdquo;&nbsp;<strong>Br J Haematol.</strong>&nbsp;2015 Jun 24. PMID: 26105212</li>
<li>Vardabasso C, Gaspar-Maia A, Hasson D, P&uuml;nzeler S, Valle-Garcia D, Straub T, Keilhauer EC, Strub T, Dong J, Panda T, Chung CY, Yao JL, Singh R, Segura MF, Fontanals-Cirera B,&nbsp;<strong>Verma A,</strong>&nbsp;Mann M, Hernando E, Hake SB, Bernstein E, &ldquo;Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma.&rdquo;&nbsp;<strong>Mol Cell.</strong>&nbsp;2015 Jun 3. PMID: 26051178</li>
<li>Sassano A, Mavrommatis E, Arslan AD, Kroczynska B, Beauchamp EM, Khuon S, Chew TL, Green KJ, Munshi HG,&nbsp;<strong>Verma AK,</strong>&nbsp;Platanias LC, &ldquo;Human Schlafen 5 (SLFN5) is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma&nbsp; Cells.&rdquo;&nbsp;<strong>Mol Cell Biol.</strong>&nbsp;2015 May 26. PMID: 26012550</li>
<li>Saleiro D, Mehrotra S, Kroczynska B, Beauchamp EM, Lisowski P, Majchrzak-Kita B, Bhagat TD, Stein BL, McMahon B, Altman JK, Kosciuczuk EM, Baker DP, Jie C, Jafari N, Thompson CB, Levine RL, Fish EN,&nbsp;<strong>Verma A,</strong>&nbsp;Platanias LC, &ldquo;Central Role of ULK1 in Type I Interferon Signaling.&rdquo;&nbsp;<strong>Cell Reports</strong>&nbsp;2015, Apr 28;11(4):605-17. PMID: 25892232</li>
<li>Cimmino L, Dawlaty MM, Ndiaye-Lobry D, Yap YS, Bakogianni S, Yu Y, Bhattacharyya S, Shaknovich R, Geng H, Lobry C, Mullenders J, King B, Trimarchi T, Aranda-Orgilles B, Liu C, Shen S,&nbsp;<strong>Verma A,</strong>&nbsp;Jaenisch R, Aifantis I, &ldquo;TET1 is a tumor suppressor of hematopoietic malignancy.&rdquo;&nbsp;<strong>Nat Immunol.</strong>&nbsp;2015 Apr 13. PMID: 25867473</li>
<li>Schinke C, Giricz O, Li W, Shastri A, Gordon S, Barreryo L, Bhagat T, Bhattacharyya S, Ramachandra N, Bartenstein M, Pellagatti A, Boultwood J, Wickrema A, Yu Y, Will W, Wei S, Steidl U*,&nbsp;<strong>Verma A*,&nbsp;</strong>&nbsp; *co-corresponding authors, &ldquo;IL8-CXCR2 pathway inhibition as a novel therapeutic strategy against MDS and AML stem cells.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2015, Mar 25. PMID: 25810490&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Porta MG, J&auml;dersten M, Dolatshad H,&nbsp;<strong>Verma A,</strong>&nbsp;Cross NC, Vyas P, Killick S, Hellstr&ouml;m-Lindberg E, Cazzola M, Papaemmanuil E, Campbell PJ, Boultwood J, &ldquo;Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic Syndromes.&rdquo;&nbsp;<strong>Nat Commun.</strong>&nbsp;2015 Jan 9;6:5901. PMID: 25574665&nbsp;</li>
<li>Caescu CI, Guo X, Tesfa L, Bhagat TD,&nbsp;<strong>Verma A,</strong>&nbsp;Zheng D, Stanley ER, &ldquo;Colony stimulating factor-1 receptor signaling networks inhibit mouse macrophage inflammatory responses by induction of microRNA-21.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2015 Jan 8. PMID: 25573988</li>
<li>Will B, Vogler TO, Narayanagari S, Bartholdy B, Todorova TI, Ferreira M, Chen J, Yu Y, Mayer J, Barreyro L, Carvajal L, Ben Neriah D, Roth M, van Oers J, Schaetzlein S, McMahon C, Edelmann W,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U, &ldquo;Minimal reduction of PU.1 is sufficient to induce a preleukemic state and promote development of acute myeloid leukemia.&rdquo;&nbsp;<strong>Nature Medicine,</strong>&nbsp;2015 (In Print)</li>
<li>Shrivastava MS, Hussain Z, Giricz O, Shenoy N, Polineni R, Maitra A,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Targeting chemokine pathways in esophageal adenocarcinoma.&rdquo;&nbsp;<strong>Cell Cycle.</strong>&nbsp;2014 Nov 1;13(21):3320-7. PMID: 25485576</li>
<li>Hu C, Mohtat D, Yu Y, Ko YA, Shenoy N, Bhattacharyya S, Izquierdo MC, Park AS, Giricz O, Vallumsetla N, Gundabolu K, Ware K, Bhagat T, Suzuki M, Pullman J, Liu SX, Greally J, Susztak K,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Kidney cancer is characterized by aberrant methylation of tissue specific enhancers that are prognostic for overall survival.&rdquo;&nbsp;<strong>Clin Cancer Res.</strong>&nbsp;2014 Jun 10. PMID: 24916699</li>
<li>Mariani CJ, Vasanthakumar A, Madzo J, Yesilkanal A, Bhagat T, Yu Y, Bhattacharyya S, Wenger R, Cohn S, Nanduri J,&nbsp;<strong>Verma A,</strong>&nbsp;Prabhakar N, Godley LA, &ldquo;TET1-Mediated Hydroxymethylation Facilitates Hypoxic Gene Induction in Neuroblastoma.&rdquo;&nbsp;<strong>Cell Rep.</strong>&nbsp;2014 May 14. PMID: 24835990</li>
<li>Keerthivasan G, Mei Y, Zhao B, Zhang L, Harris CE, Gao J, Basiorka AA, Schipma MJ, McElherne J, Yang J,&nbsp;<strong>Verma AK,</strong>&nbsp;Pellagatti A, Boultwood J, List AF, Williams DA, Ji P., &ldquo;Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) myelodysplastic syndromes.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2014 Jun 2. PMID: 24891322</li>
<li>Tamari R,&nbsp; Schinke C, Bhagat T, Roth M, Braunschweig I,&nbsp; Will B,&nbsp; Steidl U,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.&rdquo;&nbsp;<strong>Leuk Lymphoma,</strong>&nbsp;2014 Dec;55(12):2901-6.PMID: 24650011</li>
<li>Bartholdy B, Christopeit M, Will B, Mo Y, Barreyro L, Yu Y, Bhagat T, Okoye-Okafor U, Todorova T, Greally J, Levine RL, Melnick A,&nbsp;<strong>Verma A*,</strong>&nbsp;Steidl U, *Co-Corresponding, &ldquo;A human hematopoietic stem cell-commitment related DNA cytosine methylation signature is prognostic for overall survival in acute myeloid leukemia.&rdquo;&nbsp;<strong>Journal of Clinical Investigation</strong>&nbsp;2014 Feb 3 PMID: 24487588</li>
<li>Kuo P, Leshchenko V, Fazzari M, Gellen T, Iqbal J, Baumgartner-Wennerholm S, Nygren L, Zhang F, Zhang W, Suh K, Goy A, Yang D, Chan W, Kahl B,&nbsp;<strong>Verma A,</strong>&nbsp;Gascoyne R, Kimby E, Sander B, Ye BH, Melnick A, Perumal D, He T, Parekh S, &ldquo;High resolution Chromatin Immunoprecipitation (ChIP) sequencing reveals novel bindings targets and prognostic role for SOX11 in Mantle cell lymphoma.&rdquo;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oncogene,</strong>&nbsp;2014 Mar 31 PMID: 24681958</li>
<li>Hosono N, Makishima H, Jerez A, Yoshida K, Przychodzen B, McMahon S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, G&oacute;mez-Segu&iacute; I,&nbsp;<strong>Verma AK,</strong>&nbsp;McDevitt MA, Sekeres MA, Ogawa S, Maciejewski JP, &ldquo;Recurrent genetic defects on chromosome 7q in myeloid neoplasms.&rdquo;<strong>Leukemia</strong>&nbsp;2014 Jan 16. PMID: 24429498</li>
<li>Madzo J, Liu H, Rodriguez A, Vasanthakumar A, Sundaravel S, Caces DB, Looney TJ, Zhang L, Lepore JB, Macrae T, Duszynski R, Shih AH, Song CX, Yu M, Yu Y, Grossman R, Raumann B,&nbsp;<strong>Verma A,</strong>&nbsp;He C, Levine RL, Lavelle D, Lahn BT, Wickrema A, Godley LA, &ldquo;Hydroxymethylation at Gene Regulatory Regions Directs Stem/Early Progenitor Cell Commitment during Erythropoiesis.&rdquo;&nbsp;<strong>Cell Reports</strong>&nbsp;2013 Dec 24 PMID: 24373966</li>
<li>Ko YA, Mohtat D, Suzuki M, Park AS, Izquierdo MC, Han SY, Kang HM, Si H, Hostetter T, Pullman JM, Fazzari M,&nbsp;<strong>Verma A,</strong>&nbsp;Zheng D, Greally JM, Susztak K, &ldquo;Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development.&rdquo;&nbsp;<strong>Genome Biol.</strong>&nbsp;2013 Oct 7;14(10):R108. PMID: 24098934</li>
<li>Pellagatti A, Benner A, Mills K, Cazzola M, Giagounidis AAN, Perry J, Malcovati L, Giovanni M, Porta D, J&auml;dersten M,&nbsp;&nbsp;<strong>Verma A,</strong>&nbsp;McDonald E, Killick S, Hellstrom-Lindberg E, Bullinger L, Wainscoat JS, Boultwood J, &ldquo;Identification of gene expression based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.&rdquo;&nbsp;<strong>JCO</strong>&nbsp;2013 Oct 1;31(28):3557-64. PMID: 24002510</li>
<li>Lam AP, Gundabolu K, Sridharan A, Jain R, Msaouel P, Chrysofakis G, Yu Y, Friedman E, Price E, Schrier S,&nbsp;<strong>Verma AK,&nbsp;</strong>&nbsp;&ldquo;Multiplicative interaction between mean corpuscular volume and red cell distribution width in predicting mortality of elderly patients with and without anemia.&rdquo;&nbsp;&nbsp;<strong>Am J Hematol.</strong>&nbsp;2013 Nov;88(11):E245-9. PMID: 23828763</li>
<li>Yang X, Song JH, Cheng Y, Wu W, Bhagat T, Yu Y, Abraham JM, Ibrahim S, Ravich Roland W, Khashab M, Singh VK, Shin EJ, Yang X, Verma&nbsp;<strong>A,</strong>&nbsp;Meltzer SJ, Mori Y, &ldquo;Long Noncoding RNA HNF1A-AS1 Regulates Proliferation and Migration in Esophageal Adenocarcinoma Cells.&rdquo;&nbsp;<strong>Gut</strong>&nbsp;2013 Sep 2. PMID: 24000294&nbsp;</li>
<li>Bajpai M, Kessel R, Bhagat T, Nischal S, Yu Y,&nbsp;<strong>Verma A*,</strong>&nbsp;Das K, *Co-Corresponding,&nbsp; &ldquo;High resolution integrative analysis reveals widespread genetic and epigenetic changes after chronic in-vitro acid and bile exposure in Barrett's epithelium cells.&rdquo;&nbsp;<strong>Genes Chromosome Cancer</strong>&nbsp;2013 Oct 3. PMID: 24123713</li>
<li>Mehrotra S, Sharma B, Joshi S, Kroczynska B, Majchrzak B, Stein BL, McMahon B, Altman JK, Licht JD, Baker DP, Eklund EA, Wickrema A,&nbsp;<strong>Verma A,</strong>&nbsp;Fish EN, Platanias LC, &ldquo;Essential role for the Mnk-pathway in the inhibitory effects of Type I interferons on myeloproliferative neoplasm (MPN) precursors.&rdquo;&nbsp;&nbsp;<strong>JBC,</strong>&nbsp;2013 Aug 16;288(33):23814-22 PMID: 23814052</li>
<li>Bhattacharyya, Si; Yu, Y; Suzuki, M; Campbell, N; Mazdo, J; Vasantkumar, A; Bhagat, T; Nischal, S; Christopeit, M; Parekh, S; Steidl, U; Godley, L; Maitra, A; Greally, J;&nbsp;<strong>Verma, A;&nbsp;</strong>&nbsp;&ldquo;Genome wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer.&rdquo;&nbsp;<strong>Nucleic Acid Res</strong>&nbsp;2013&nbsp; Sep;41(16):e157 PMID: 23861445</li>
<li>Will B, Vogler TO, Bartholdy B, Garrett-Bakelman F, Mayer J, Barreyro L, Pandolfi A, Todorova TI, Okoye-Okafor UC, Stanley RF, Bhagat TD,&nbsp;<strong>Verma A,</strong>&nbsp;Figueroa ME, Melnick A, Roth M, Steidl U, &ldquo;Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment.&rdquo;&nbsp;<strong>Nat Immunol.</strong>&nbsp;2013 May;14(5):437-45. PMID: 23563689</li>
<li>Bhagat T, Zhou L, Sokol L, Caceres G, Gundabolu K, Gordon S, Mantzaris I, Gligich O, Yu Y, Bhattacharyya S, Jing X, Polineni R, Tamari R, Bhatia K, Pellagatti A , Boultwood J, Kambhampati S, Steidl U, Stein C, Ju W, Liu G, Kenny P, List A, Bitzer M,&nbsp;<strong>Verma A,&nbsp;</strong>&nbsp;&ldquo;miR-21 mediates hematopoietic suppression in MDS by activating TGF-bsignaling.&rdquo;&nbsp;<strong>Blood</strong>&nbsp;2013, Apr 11;121(15):2875-81. PMID: 23390194</li>
<li>Yu Y, Mo Y, Liu H, Bhattacharyya S, Ebenezer D, Sundaravel S, Caces B, Ulaszek J, Artz A, Nischal S, Bhagat T, Bathon K, Maqbool S, Suzuki M, Steidl U, Godley L, Skoultchi A, Greally J, Wickrema A,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;High resolution methylome analysis reveals widespread hypomethylation during human erythroid differentiation.&rdquo;&nbsp;<strong>JBC</strong>&nbsp;2013 Mar 29;288(13):8805-14. PMID: 23306203</li>
<li>Heuck C, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, Pulliam N, Nischal S, Zhou L, Bhattacharya S, Meagher R, Hu C, Maqbool S, Suzuki M, Parekh S, Reu F, Steidl U, Greally J,<strong>&nbsp;Verma A*,</strong>&nbsp;Singhal S,* Co-Corresponding, &ldquo;Myeloma is characterized by stage specific alterations in DNA methylation that occur early during myelomagenesis.&rdquo; &nbsp;<strong>Journal of Immunology</strong>&nbsp;2013 Mar 15;190(6):2966-75. PMID: 23408834</li>
<li>Wu W, Bhagat T, Yang X, Song J, Cheng Y, Agarwal R, Abraham J, Ibrahim S, Bartenstein M, Hussain Z, Suzuki M, Yu Y, Eng C, Greally J,&nbsp;<strong>Verma A*,</strong>&nbsp;Meltzer SJ*, Co-Corresponding, &ldquo;Hypomethylation of Noncoding DNA Regions and Overexpression of the Long Noncoding RNA, AFAP1-AS1, in Barrett&rsquo;s Esophagus and Esophageal Adenocarcinoma.&rdquo;&nbsp;<strong>Gastroenterology</strong>&nbsp;2013 May;144(5):956-966. PMID: 23333711</li>
<li>Nischal S, Bhattacharyya S, Christopeit N, Yu Y, Zhou L, Bhagat T, Sohal S, Will B, Mo Y, Suzuki M, Pardanani A, McDevitt M, Maciejewski J, Melnick A, Greally J, Steidl U, Moliterno A,&nbsp;<strong>Verma A,&nbsp;</strong>&nbsp;&ldquo;Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.&rdquo;&nbsp;<strong>Cancer Res,</strong>&nbsp;2012 Dec 27. PMID: 23066032</li>
<li>Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C,Tamari R, Yu Y, Bhagat T,&nbsp; Bhattacharya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, Boultwood J, Montagna C, Silverman L, Maciejewski J, Greally JM, Ye BH, List AF, Steidl C, Steidl U,&nbsp;<strong>Verma A,&nbsp;</strong>&nbsp;&ldquo;Stem and progenitor cells in myelodysplastic syndromes show aberrant stage specific expansion and harbor genetic and epigenetic alterations.&rdquo;&nbsp;<strong>Blood</strong>&nbsp;2012; 120(10):2076-86. PMID: 22753872</li>
<li>Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R,&nbsp;<strong>Verma A,</strong>&nbsp;Garcia-Manero G, Li YP, Lowe A, Zhu J, List AF, &ldquo;Randomized, dose-escalation study of the p38&alpha; MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome.&rdquo;&nbsp;<strong>Leukemia.</strong>&nbsp;2012 Sep 11. PMID: 23032694</li>
<li>Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L, Fernandez, Greenberg PL, Tallman MS, Steidl C, Mitsiades CS,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U, &ldquo;Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2012 Aug 9;120(6):1290-8. PMID: 22723552</li>
<li>Jerez A, Sugimoto Y, Makishima H,&nbsp;<strong>Verma A,</strong>&nbsp;Jankowska AM, Przychodzen B, Visconte V, Tiu RV, O'Keefe CL, Mohamedali AM, Kulasekararaj AG, Pellagatti A, McGraw K, Muramatsu H, Moliterno AR, Sekeres MA, McDevitt MA, Kojima S, List A, Boultwood J, Mufti GJ, Maciejewski JP,&nbsp; &ldquo;Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis.&rdquo;&nbsp;&nbsp;&nbsp;<strong>Blood.</strong>&nbsp;2012 Jun 21;119(25):6109-17. PMID: 22553315</li>
<li>Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U., &ldquo;Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2012 May 24. PMID: 22627766</li>
<li>Barta SK, Zou Y, Schindler J, Shenoy N, Bhagat TD, Steidl U,&nbsp;<strong>Verma A.,</strong>&nbsp;&ldquo;Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia.&rdquo;&nbsp;<strong>Leuk Lymphoma</strong>.2012 Apr 18.&nbsp; PMID: 22448921</li>
<li>Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL,<strong>&nbsp;Verma A,</strong>&nbsp;Maciejewski JP, McDevitt MA, Moliterno AR, &ldquo;Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.&rdquo;&nbsp;&nbsp;&nbsp;<strong>Haematologica.</strong>&nbsp;2011 Oct;96(10):1462-9. Epub 2011 Jun 28. PMID: 21712540</li>
<li>Sharma B, Altman JK, Goussetis DJ,&nbsp;<strong>Verma AK,</strong>&nbsp;Platanias LC, &ldquo;Protein kinase R as mediator of the effects of interferon (IFN) gamma and tumor necrosis factor (TNF) alpha on normal and dysplastic hematopoiesis.&rdquo;&nbsp;<strong>J Biol Chem.</strong>&nbsp;2011 Aug 5;286(31):27506-14. Epub 2011 Jun 9. PMID:1659535</li>
<li>Zhou L, Opalinska J, Sohal D, Yu Y, Mo Y, Bhagat T, Abdel-Wahab O, Fazzari M, Figueroa M, Alencar C, Zhang J, Kanbhampati S, Parmar S, Nischal S, Heuck C, Suzuki M, Friedman E, Pellagatti A, Boultwood J, Steidl U, Sauthararajah Y, Yajnik V, Gore SD, Platanias LC, Levine R, Melnick A, Wickrema A, Greally JM,&nbsp;<strong>Verma A,&nbsp;</strong>&nbsp;&ldquo;Aberrant epigenetic and genetic marks are seen in myelodysplastic leucocytes and reveal DOCK4 as a candidate pathogenic gene on chr7q.&rdquo;&nbsp;<strong>J Biol Chem.</strong>&nbsp;2011 Apr 30. PMID: 21532034&nbsp;</li>
<li>Alvarez H, Opalinska J, Zhou L, Sohal D, Fazzari M, Yu Y, Montagna C, Montgomery E, Canto M, Dunbar K, Wang J, Roa J, Mo Y, Bhagat T, Ramesh K, Cannizzaro L, Mollenhauer J, Thompson R, Suzuki M, Meltzer S, Melnick A, Greally JM, Maitra A,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis.&rdquo;&nbsp;<strong>PLOS Genetics</strong>&nbsp;2011 Mar;7(3) PMID: 21483804</li>
<li>L Zhou, C McMahon, T Bhagat, C Alencar, Y Yu, M Fazzari, D Sohal, C Heuck, K Gundabolu, C Ng, Y Mo, W Shen, A Wickrema, G Kong, E Friedman, L Sokol,&nbsp; G Mantzaris, A Pellagatti , J Boultwood, LC Platanias, U Steidl, L Yan, JM Yingling, MM Lahn, A List, M Bitzer and&nbsp;<strong>A Verma,</strong>&nbsp;&ldquo;Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.&rdquo;&nbsp;<strong>Cancer Research</strong>&nbsp;2011 Feb 1;71(3):955-63.PMID: 21189329</li>
<li>Joshi S, Sharma B, Kaur S, Majchrzak B, Ueda T, Fukunaga R,<strong>&nbsp;Verma AK,</strong>&nbsp;Fish EN, Platanias LC, &ldquo;Essential role for Mnk kinases in type II interferon (IFNgamma) signaling and its suppressive effects on normal hematopoiesis.&rdquo;&nbsp;&nbsp;<br />
<strong>J Biol Chem.</strong>&nbsp;2011 Feb 25;286(8):6017-26.PMID: 21149447</li>
<li>Kroczynska B, Joshi S, Eklund EA,&nbsp;<strong>Verma A,</strong>&nbsp;Kotenko SV, Fish EN, Platanias LC, &ldquo;Regulatory effects of ribosomal S6 kinase 1 (RSK1) in IFN&lambda; signaling.&rdquo;&nbsp;<strong>J Biol Chem.</strong>&nbsp;2011 Jan 14;286(2):1147-56. Epub 2010 Nov 12.</li>
<li>Schinke C, Goel S, Bhagat TD, Zhou L, Mo Y, Gallagher R, Kabalka GW, Platanias LC,&nbsp;<strong>Verma A*,</strong>&nbsp;Das B, &ldquo;Design and synthesis of novel derivatives of all-trans retinoic acid demonstrate the combined importance of acid moiety and conjugated double bonds in its binding to PML-RAR-alpha oncogene in acute promyelocytic leukemia.&rdquo;&nbsp;<br />
<strong>Leuk Lymphoma.</strong>&nbsp;2010 Jun;51(6):1108-14. PMID: 20536349</li>
<li>Huh J, Tiu RV, Gondek LP, O'Keefe CL, Jasek M, Makishima H, Jankowska AM, Jiang Y,&nbsp;<strong>Verma A,</strong>&nbsp;Theil KS, McDevitt MA, Maciejewski JP, &ldquo;Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.&rdquo;&nbsp;<strong>Genes Chromosomes Cancer.</strong>&nbsp;2010 Apr;49(4):390-9. PMID: 20095039</li>
<li>Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, J&auml;dersten M,&nbsp;<strong>Verma A,</strong>&nbsp;Norbury C Hellstr&ouml;m-Lindberg E, Wainscoat JS, Boultwood J, &ldquo;Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.&rdquo;&nbsp;<strong>Leukemia.</strong>&nbsp;2010 Apr;24(4):756-64. PMID: 20220779</li>
<li>Einstein F, Thompson RF, Bhagat TD, Fazzari MJ,&nbsp;<strong>Verma A,</strong>&nbsp;Barzilai N, Greally JM, &ldquo;Cytosine methylation dysregulation in neonates following intrauterine growth restriction.&rdquo;&nbsp;<strong>PLoS One.</strong>&nbsp;2010 Jan 26;5(1):e8887 PMID: 20126273</li>
<li>Oda M., Glass J.L., Thompson R.F., Mo Y., Olivier E., Figueroa M.E., Selzer R.R., Richmond T.A., Zhang X., Dannenberg L., Green R., Melnick A., Hatchwell E., Bouhassira E.,&nbsp;<strong>Verma A.,</strong>&nbsp;Suzuki M., Greally J.M., &ldquo;High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers.&rdquo;&nbsp;<strong>Nucleic Acids Res.</strong>&nbsp;2009 Jul;37(12):3829-39.&nbsp;&nbsp; PMID: 19386619</li>
<li>Sohal D, Yeatts A, Ye K, Pellagatti A, Zhou L, Pahanish P, Mo Y, Bhagat T, Mariadason J, Boultwood J, Melnick A, Greally JM,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration.&rdquo;&nbsp;<strong>PLOS One</strong>&nbsp;2008 Aug 13;3(8):e2965&nbsp;&nbsp;&nbsp; PMID: 18698424</li>
<li>Zhou L, Nguyen AN, Sohal D, Ma JY, Pahanish P, Gundabolu K, Hayman J, Chubak A,&nbsp;&nbsp; Mo Y, Bhagat T, Das B, Haghnazari E, Navas T, Parmar S, Kambhampati S, Pellagati A,&nbsp; Braunchweig I, Zhang YE, Wickrema A, Boultwood J, Platanias LC, Higgins LS, List A, Bitzer M,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Inhibition of Transforming Growth Factor beta receptor I kinase can stimulate hematopoiesis in Myelodysplasia.&rdquo;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>Blood</strong>&nbsp;2008 Oct 15;112(8):3434-43&nbsp; PMID: 18474728</li>
<li>Navas T, Zhou L, Estes M, Haghnazari E, Nguyen A, Mo Y, Pahanish P, Mohindru M, Cao T, Higgins L, Platanias LC, List A,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Inhibition of p38a MAPK disrupts the pathological loop of proinflammatory factor production in the Myelodysplastic Syndrome bone marrow microenvironment.&rdquo; &nbsp;<strong>Leukemia and Lymphoma</strong>&nbsp;2008 Oct;49(10):1963-75</li>
<li>Zhou L, Opalinska J,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;p38 MAP kinase regulates stem cell apoptosis in human hematopoietic failure.&rdquo;&nbsp;<strong>Cell Cycle&nbsp;</strong>2007<strong>,</strong>&nbsp;1;6(5):534</li>
<li>Navas T, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P,&nbsp;Parmar S, Haghnazari E, Zhou L, Collins RC, Kerr I, Nguyen A, Xu Y, Platanias LC, List AA, Higgins LS,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.&rdquo;&nbsp;<strong>Blood&nbsp;</strong>2006, 15;108(13):4170-7</li>
<li><strong>Verma A,</strong>&nbsp;and List A, &ldquo;Cytokine Targets in Myelodysplastic syndromes.&rdquo;&nbsp;<strong>Current Hematology Reports</strong>&nbsp;2005 Nov;4(6):429-35</li>
<li>Deonarain R,&nbsp;<strong>Verma A,</strong>&nbsp;Porter AC, Gewert DR, Platanias LC, Fish EN, &ldquo;Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha.&rdquo;&nbsp;<strong>Proc Natl Acad Sci USA.</strong>&nbsp;2003 Nov 11;100(23):13453-8</li>
<li><strong>Verma A,</strong>&nbsp;Devine S, Morrow M, Chen YH, Mihalov M, Peace D, Stock W, Pursell K, Wickrema A, Yassine M, Jessop E, Van Besien K, &ldquo;Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.&rdquo;&nbsp;&nbsp;<strong>Bone Marrow Transplant.</strong>&nbsp;2003 May;31(9):813-6.</li>
<li><strong>Verma A.,</strong>&nbsp;Mohindru M., Deb D., Sassano A., Kambhampati S., Minucci S., Ravandi F., Kovakanalu D, Platanias L., &ldquo;Activation of the Rac1 and p38 MAP kinase pathway in response to Arsenic trioxide.&rdquo;&nbsp;&nbsp;<strong>Journal of Biological Chemistry</strong>&nbsp;22;277(47):44988-95</li>
<li><strong>Verma A,</strong>&nbsp;Sassano A, Deb D, Wickrema, A., VanBesien K., and Platanias L., &ldquo;Blockade of p38 MAP kinase reverses cytokine mediated inhibition in aplastic anemia.&rdquo;&nbsp;<strong>Journal of Immunology</strong>&nbsp;2002, 168 (12) (Cutting edge section)</li>
<li><strong>Verma A,</strong>&nbsp;Deb D.K., Sassano A., Uddine S., Wickrema A., Varga and Platanias LC, &ldquo;Activation of the p38 mitogen activated protein kinase mediates suppressive effects of Type I interferons and transforming growth factor-b on normal hematopoiesis.&rdquo;&nbsp;<strong>Journal of Biological Chemistry</strong>&nbsp;2002, 277(10):7726-35</li>
<li>Devine S, Hoffman R,&nbsp;<strong>Verma A,</strong>&nbsp;Shah R, Bradlow B, Stock W and Van Besien K, &ldquo;Allogeneic blood cell transplantation following reduced intensity conditioning is effective therapy for older patients with myelofibrosis.&rdquo;<strong>&nbsp;Blood&nbsp;</strong>&nbsp;2002, 99(6):2255-8</li>
</ol>
<p><strong>Review articles</strong></p>
<ol start="1" type="1">
<li>Li W, Morrone K, Kambhampati S, Will B, Steidl U,&nbsp;<strong>Verma A,&nbsp;</strong>&ldquo;Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.&rdquo;&nbsp;<strong>Leukemia,&nbsp;</strong>2015 (In Press)</li>
<li>Shenoy N, Vallumsetla N, Zou Y, Galeas JN, Shrivastava M, Hu C, Susztak K,&nbsp;<strong>Verma A.,&nbsp;</strong>"Role of DNA methylation in renal cell carcinoma."&nbsp;<strong>J Hematol Oncol.</strong>&nbsp;2015 Jul 22;8(1):88. PMID: 26198328</li>
<li><strong>Verma A,</strong>&nbsp;Steidl U., &ldquo;A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia.&rdquo;&nbsp;<br />
<strong>Nat Med.</strong>&nbsp;2015;21:113-4.&nbsp; PMID: 25654599</li>
<li>Ga&ntilde;&aacute;n-G&oacute;mez I, Wei Y, Starczynowski DT, Colla S, Yang H, Cabrero-Calvo M, Bohannan ZS,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U, Garcia-Manero G, "Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes."&nbsp;<strong>Leukemia.</strong>&nbsp;2015 Mar 12. PMID: 25761935</li>
<li>Shenoy N, Vallumsetla N,&nbsp; Rachmilewitz E,&nbsp;<strong>Verma A,</strong>&nbsp;Ginzburg Y., "Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome."&nbsp;<strong>Blood,</strong>&nbsp;2014 Aug 7;124(6):873-81. PMID: 24923296</li>
<li>Das BC, Thapa P, Karki R, Das S, Mahapatra S, Liu TC, Torregroza I, Wallace DP, Kambhampati S, Van Veldhuizen P,&nbsp;<strong>Verma A,</strong>&nbsp;Ray SK,&nbsp;&nbsp;&nbsp; Evans T.,&nbsp; "Retinoic acid signaling pathways in development and diseases."<br />
<strong>Bioorg Med Chem.</strong>&nbsp;2014 Jan 15;22(2):673-83. PMID: 24393720</li>
<li>Elias HK, Schinke C, Bhattacharyya S, Will B*,&nbsp;<strong>Verma A*,&nbsp;</strong>&nbsp;Steidl U* *CoCorresponding,&nbsp;&nbsp;&nbsp; &ldquo;Stem cell origin of myelodysplastic syndromes.&rdquo;&nbsp;<strong>Oncogene</strong>&nbsp;2013 Dec 16. PMID: 24336326</li>
<li>Pathak S, Roth M,&nbsp;<strong>Verma A*,</strong>&nbsp;Steidl U*.&nbsp; *CoCorresponding,&nbsp;&nbsp;&nbsp; &ldquo;Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.&rdquo;<br />
<strong>Expert Opin Drug Metab Toxicol.</strong>&nbsp;2013 Dec;9(12):1667-75. PMID: 24215532</li>
<li>Feld J, Barta SK, Schinke C, Braunschweig I, Zhou Y,&nbsp;<strong>Verma AK,&nbsp;&nbsp;</strong>&ldquo;Linked-in: design and efficacy of antibody drug conjugates in oncology.&rdquo;&nbsp;<strong>Oncotarget</strong>&nbsp;2013 Mar;4(3):397-412. PMID: 23651630</li>
<li>Khan H, Vale C, Bhagat T,&nbsp;<strong>Verma A.,&nbsp;&nbsp;&nbsp;</strong>&ldquo;Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.&rdquo;<br />
<strong>Semin Hematol.</strong>&nbsp;2013 Jan;50(1):16-37. PMID: 23507481</li>
<li>Elias H,&nbsp;<strong>Verma A,&nbsp;&nbsp;</strong>&ldquo;Activation of hypoxia signaling is marker of poor prognosis in myelodysplasia.&rdquo;<br />
<strong>Leuk Lymphoma.</strong>&nbsp;2012 Dec;53(12):2337-8. PMID: 22897726</li>
<li>Shenoy N, Kessel R, Bhagat TD, Bhattacharyya S, Yu Y, McMahon C,&nbsp;<strong>Verma A.,&nbsp;&nbsp;</strong>&ldquo;Alterations in the ribosomal machinery in cancer and hematologic disorders.&rdquo;&nbsp;<strong>J Hematol Oncol.</strong>&nbsp;2012 Jun 18;5:32. PMID: 22709827</li>
<li>Agarwal A, Polineni R, Hussein Z, Vigoda I, Bhagat TD, Bhattacharyya S, Maitra A,&nbsp;<strong>Verma A.,&nbsp;&nbsp;</strong>&ldquo;Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.&rdquo;&nbsp;<strong>Int J Clin Exp Pathol.</strong>&nbsp;2012;5(5):382-96. PMID: 22808291</li>
<li>Sharma A,&nbsp; Heuck C, Fazzari M, Mehta J, Singhal S, Greally JM,&nbsp;<strong>Verma A,&nbsp;&nbsp;</strong>&ldquo;DNA methylation alterations seen in myeloma as a model of epigenetic changes in cancer.&rdquo;&nbsp;<strong>WIREs Systems Biology and Medicine</strong>&nbsp;2010 Nov-Dec;2(6):654-69. PMID: 20890963</li>
<li>Schinke C, Mo Y, Yu Y, Amiri K, Sosman J, Greally JM,&nbsp;<strong>Verma A,&nbsp; &ldquo;</strong>Aberrant DNA methylation in malignant melanoma.&rdquo;&nbsp;<strong>Melanoma Research</strong>&nbsp;2010, Aug; 20(4):253-65 PMID: 20418788</li>
<li>Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B,&nbsp;<strong>Verma A.,&nbsp;</strong>&ldquo;Mechanism of action of lenalidomide in hematological malignancies.&rdquo;<br />
<strong>J Hematol Oncol.</strong>&nbsp;2009 Aug 12;2:36</li>
<li>Opalinska J, Zhou L,&nbsp;<strong>Verma A.,&nbsp;</strong>&ldquo;A new PML-RARs fusion transcript hints at the important role of PML dysregulation in the pathogenesis of APL.&rdquo;&nbsp;<strong>Leukemia Research (Commentary)</strong>&nbsp;2007, 48(3):443</li>
<li>Isufi I, Seetharam M, Sohal D, Zhou L, Opalinska J, Pahanish P,&nbsp;<strong>Verma A., &ldquo;</strong>Transforming Growth Factor-beta Signaling in Normal and Malignant Hematopoiesis.&rdquo;&nbsp;<strong>Journal of Interferon and Cytokine Research</strong>&nbsp;2007, 27(7):543</li>
<li>Mohindru M,&nbsp;<strong>Verma A,&nbsp;&nbsp;</strong>&ldquo;Engineered antibodies act as targeted therapies in cancer treatment.&rdquo;&nbsp;<strong>Indian Journal of Pediatrics,</strong>&nbsp;2005 Nov;72(11):943-7</li>
<li>Sassano A,&nbsp;<strong>Verma A,</strong>&nbsp;Platanias LC, "Mitogen-activated protein kinase pathways in interferon signaling."&nbsp;<strong>Methods Molecular Medicine,</strong>&nbsp;2005;116:135-50.</li>
<li>Mohindru M,&nbsp;<strong>Verma A,&nbsp;</strong>"Kinase inhibitors translate lab discoveries into exciting new cures for cancers."&nbsp;<strong>Indian Journal of Pediatrics,</strong>&nbsp;2004 Aug;71(8):713-8.</li>
<li><strong>Verma A,</strong>&nbsp;Kambhampati S, Parmar S, Platanias LC,&nbsp; &ldquo;Jak family of kinases in cancer.&rdquo;&nbsp;<strong>Cancer Metastasis Rev.</strong>&nbsp;2003 Dec;22(4):423-34.(rev)</li>
<li><strong>Verma A,</strong>&nbsp;and Platanias LC, &ldquo;Signaling via the interferon-a receptor in chronic myelogenous leukemia cells.&rdquo;&nbsp;<strong>Leukemia and Lymphoma&nbsp;</strong>&nbsp;2002, 44:703-709</li>
<li><strong>Verma A,</strong>&nbsp;and Stock W, &ldquo;Management of adult lymphoblastic leukemia: moving toward a risk-adapted approach.&rdquo;&nbsp;<strong>Current Opinion in Oncology,</strong>&nbsp;2001, 13:14-20</li>
<li><strong>Verma A,</strong>&nbsp;and Gupta YK,&nbsp; &ldquo;The search for a super oral rehydration solution (0RS).&rdquo;&nbsp;<strong>Drugs: News and Views,</strong>&nbsp;1995, 3(2):129-132.&nbsp;</li>
</ol>

EMR ID
4772
Biography

<p>Amit K. Verma, MD, is Interim Chair, Department of Oncology, Associate Director of Translational Science, Montefiore Einstein Comprehensive Cancer Center, Professor, Medical Oncology and Professor, Developmental & Molecular Biology, Albert Einstein College of Medicine.</p><p>Dr. Verma earned his Doctor of Medicine at the All India Institute of Medical Sciences in 1995 and finished his training in internal medicine, hematology oncology and stem cell transplantation at the University of Illinois and Northwestern University in 2003.</p><p>Dr. Verma conducts clinical studies for patients with MDS and leukemia and offers a variety of clinical trials for these patients. He conducts laboratory research aimed at discovering new treatments for myelodysplastic syndromes (MDS) and leukemias, and his research has shown that the TGF-beta superfamily/smad, IRAK and MAP kinase pathways are overactivated in MDS. His work has led to clinical trials with Luspatercept, Galunisertib, CA4948, ARRY-614 and various other promising agents in MDS. DR. Verma&rsquo;s research has shown that MDS and leukemias are caused by aberrant leukemic stem cells and has identified novel targets against MDS/AML stem cells that are being tested in various studies.</p><p>Dr. Verma is a scholar of the Leukemia and Lymphoma society, elected member of American society of clinical investigation and his research is funded by the NIH, Department of Defense, American Cancer Society, Edward P. Evans Foundation and various other private foundations.</p>

Is Open Scheduling
Off

Henry M. Ushay

Submitted by Anonymous (not verified) on
Full Name
Henry Michael Ushay
Profile Image URL
https://assets.montefioreeinstein.org/profiles/images/physphoto/Ushay_Michael_MD_420x504.jpg
Type
Provider
Faculty
First Name
Henry
Last Name
Ushay
NPI
1558332007
Faculty ID
10275
Clinical Terms
Employment Status
Full Time
Patient Type
Pediatric
Department
einstein-dept-pediatrics
Gender
Male
Email
hmushay@montefiore.org
Phone
718-920-4321
Titles
Type
Academic
Department
Department of Pediatrics
Department Link
Rank
Professor
Tags
me-patientcare-transplant-team
Division
Pediatric Critical Care
Type
Clinical
Title
Professor of Pediatrics, Albert Einstein College of Medicine
Type
Administrative
Locations
Is Primary
On
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.87885 40.88037)
Address Line 1
3415 Bainbridge Avenue
City
Bronx
State
NY
Zip
10467-2403
Location Title
The Children's Hospital at Montefiore
Is Primary
Off
Type
Academic
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.8798833 40.8799447)
Building
Rosenthal Pavilion
Room
422
Address Line 1
Montefiore Medical Center
Address Line 3
111 East 210th Street
City
Bronx
State
NY
Zip
10467
Location Title
Montefiore Medical Center
Education and Trainings
Education Type Label
Medical Education
Education Institution
University of Medicine & Dentistry of New Jersey
Education Type Label
Fellowship
Education Institution
Montefiore Medical Center
Education Type Label
Fellowship
Education Institution
New York Hospital - Cornell Medical Center
Education Type Label
Residency
Education Institution
Montefiore Medical Center
CHAM Provider
On
Professional Title
M.D.
Ph.D.
Clinical Focus

Pediatric critical care medicine with a special emphasis on respiratory failure; shock resuscitation; cardiac intensive care; intensive care of pediatric oncology patients; extracorporeal support for children with respiratory and cardiovascular failure

Research Focus

Leadership and direction of the 16-bed Pediatric Critical Care Unit of The Children&rsquo;s Hospital at Montefiore; improving medication safety; respiratory physiology; advances in the management of respiratory failure in children; shock; medical ethics

EMR ID
4763
Biography

<p>Dr. Ushay is Professor of Clinical Pediatrics in the Albert Einstein College of Medicine. He is a Fellow of the American Academy of Pediatrics as well as a Fellow of the American College of Critical Care Medicine. </p><p>After obtaining a PhD in Chemistry from Columbia University, Dr. Ushay received his MD from UMDNJ-New Jersey Medical School and completed a Pediatrics residency in the Montefiore-Jacobi-Einstein program. After serving as Chief Resident and a Fellow in Pediatric Pulmonology at Montefiore, he completed a Pediatric Critical Care Fellowship at New York Hospital/Cornell Medical Center in 1993. He was a faculty member at NewYork-Presbyterian and Memorial Sloan-Kettering Hospitals from 1993 to 2005, and he served as Pediatric Critical Care Medicine Fellowship Program Director and Medical Director of the Pediatric Observation Unit at Memorial Sloan-Kettering Cancer Center. </p><p>In 2005 Dr. Ushay became Director of the Pediatric Critical Care Unit in The Children&rsquo;s Hospital at Montefiore. Dr. Ushay is involved in increasing pediatric ICU surge capacity through the New York City Pediatric Disaster Coalition, serving on its Central Leadership Council and teaching the Pediatric Fundamental Critical Care Support Course. Through the National Institute of Child Health and Human Development, Dr. Ushay works on employing medical countermeasures safely for children in the event of chemical, biological or radiological disaster. Sponsored by Surgeons of Hope and Children&rsquo;s HeartLink, Dr. Ushay has worked as a cardiac intensivist in Cambodia, Africa, China and Nicaragua. </p>

Is Open Scheduling
Off
Subscribe to Anemia Of Chronic Disease